Here’s a charming little piece of video.

Get to about 35 seconds when fauci funded peter daszak starts speaking in his own words about working to make SARS like viruses in animals infect humans by hotwiring their spike proteins.

This is what he says (my transcription, may have a couple minor errors, but i think it’s pretty much accurate.)

“you get a virus that looks like a relative of a known, nasty pathogen, just like we did with SARS and other coronaviruses in bats, a whole host of them, some of them looked very similar to SARS so we sequenced the spike protein, the protein that attaches to cells.

then we, well, i didn’t do this work but my colleagues in china did (he’s speaking here of wuhan institute of virology) you create pseudo-particles, you insert the spike proteins from those viruses to see if they bind to human cells.

each step of this you move closer and closer to “this virus could really become pathogenic in people.” so, you narrow down the field, you reduce the costs and you end up with a small number of viruses that really do look like killers….”

(i have downloaded this video in case it gets pulled. let me know if it does)

January 13th 2022 49 Retweets 57 Likes

this is EXACTLY what i have long said and suspected.

the work in wuhan was absolutely gain of function work. it was NOT work on weaponization. it was the mad scientist lunacy that daszak submitted to DARPA and they rejected but that fauci then funded through the NIAID.

they were making “killers” to see if they could find cures.

oopsie.

peter daszak: supervillain origin story

this was an attempt to predict what viruses MIGHT one day jump from bats to humans and to work on vaccines for them. that’s why he speaks of “narrowing down the field.”

this is literally: let’s find a possible risk and make it real. let’s see if we can add function and virulence to a pathogen until it’s a serious threat to humans and then see if we can immunize against it in case something like that ever happens one day.
talk about a self fulfilling prophesy...

they did it in china because work like this is too crazy to be allowed unsupervised in the US. (or likely allowed at all) and they broke all the rules of their grant and took to 10,000X what should have been limited to 10X (itself already extremely risky). and the NIH knew that. and they did nothing.

more:

“if you go past hotwiring viruses to produce 10X the viral load you need to tell us” that alone is a terrifying basis for a grant’s conditions. “we went to 1,000 to 10,000X and did not tell you.”

it’s also likely why the NIH (of which NIAID is a part) happened to have access to the payload for an mRNA vaccine ready to go and licensed it to moderna an impossible 10 days after SARSCOV-2 was officially claimed to have been sequenced.
this has been in the works for years.
it also looks to have been half baked, untested, and we’ve all seen how THAT worked out.
this makes me suspect that the leak was accidental (though likely telegraphed to a number of insiders well before it was public.)

just how this same sort of tech made it to biontech (who then licensed it to pfizer) and how billy “pandemia” gates knew to buy a big chunk of the company in november of 2019 right before they cut that pfizer deal remains an open and interesting question.

but all pieces keep falling into place.

• this was an ill conceived vaccine program run in china by people who, based on their DARPA submission, were barking mad. (read the daszak piece linked above. what he proposes to do in wuhan was literally mad scientist crazy)

• it was funded by fauci after DARPA said no.

• it was in the EXACT virus that became SARSCOV-2 in the exact location in which it appeared.

• and it used the exact methods that led to the utterly improbable if not impossible gene signatures that many used early on to claim this was a lab escape before being buried under what has now clearly been shown to have been a concerted cover up.

i’m just not seeing any other way to explain this that does not require 3 or 4 ten million to one coincidences piled on top of one another.
we may never get the full story. it’s not like china is going to help.
but it’s all here somewhere and enough has surfaced that the mosaic is getting hard to miss.

it all needs to be dragged out into the light because until it is, we’re not safe.

we’re not safe from this happening again because such research is ongoing.
but we’re also not safe from outright blackmail and espionage.
think about it. china has the NIH over a barrel. they will have to do ANYTHING they are told and NIH funds everything.

they have their fingers in half the early stage disease research in the US.

they are the gold givers of the research system.

nearly every university virology department is beholden and so are all the university researchers that were involved with this wuhan scandal.

imagine you’re someone like professor baric at UNC and you wound up doing something like this:

(from DARPA grant ap)

how you feeling right now? how will you respond when a chinese intelligence agent demands that you procure and provide sensitive data and research from your university or they will leak your actions to the press?

this is precisely how one would cultivate such an asset.
and all this is a wide open, gaping vulnerability until we rip it out and cauterize the wound. it’s a blackmail bonanza.
these guys have been scrambling from the start to hide this.
and this is why we HAVE to get to the bottom of it no matter how embarrassing these revelations may be.

time to put our top people on it and allow no further whitewash.

Dr. Robert Malone is the inventor of the nine original mRNA vaccine patents, which were originally filed in 1989 (including both the idea of mRNA vaccines and the original proof of principle experiments) and RNA transfection. Dr. Malone, has close to 100 peer-reviewed publications which have been cited over 12,000 times. Since January 2020, Dr. Malone has been leading a large team focused on clinical research design, drug development, computer modeling and mechanisms of action of repurposed drugs for the treatment of COVID-19. Dr. Malone is the Medical Director of The Unity Project, a group of 300 organizations across the US standing against mandated COVID vaccines for children. He is also the President of the Global Covid Summit, an organization of over 16,000 doctors and scientists committed to speaking truth to power about COVID pandemic research and treatment.

Much more data and elaboration at original source.

• Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant after exclusions. 49 studies from 45 independent teams in 21 different countries show statistically significant improvements in isolation (37 primary outcome, 34 most serious outcome).
• Meta analysis using the most serious outcome shows 66% [53‑75%] and 83% [74‑89%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (excluding all GMK/BBC team studies), for primary outcomes, for peer-reviewed studies, and for RCTs.
• Results are very robust — in worst case exclusion sensitivity analysis 60 of 76 studies must be excluded to avoid finding statistically significant efficacy.
• While many treatments have some level of efficacy, they do not replace vaccines and other measures to avoid infection. Only 25% of ivermectin studies show zero events in the treatment arm.
• Multiple treatments are typically used in combination, which may be significantly more effective.
• Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used, including treatments, as supported by Pfizer [Pfizer, TrialSiteNews]. Denying the efficacy of treatments increases mortality, morbidity, collateral damage, and endemic risk.

...

1. Peter Doshi, senior editor,

2. Fiona Godlee, former editor in chief,

3. Kamran Abbasi, editor in chief

4. The BMJ, London, UK

5. Correspondence to: P Doshi Pdoshi{at}bmj.com

Data should be fully and immediately available for public scrutiny

In the pages of The BMJ a decade ago, in the middle of a different pandemic, it came to light that governments around the world had spent billions stockpiling antivirals for influenza that had not been shown to reduce the risk of complications, hospital admissions, or death. The majority of trials that underpinned regulatory approval and government stockpiling of oseltamivir (Tamiflu) were sponsored by the manufacturer; most were unpublished, those that were published were ghostwritten by writers paid by the manufacturer, the people listed as principal authors lacked access to the raw data, and academics who requested access to the data for independent analysis were denied.1234

The Tamiflu saga heralded a decade of unprecedented attention to the importance of sharing clinical trial data.56 Public battles for drug company data,78 transparency campaigns with thousands of signatures,910 strengthened journal data sharing requirements,1112 explicit commitments from companies to share data,13 new data access website portals,8 and landmark transparency policies from medicines regulators1415 all promised a new era in data transparency.

Progress was made, but clearly not enough. The errors of the last pandemic are being repeated. Memories are short. Today, despite the global rollout of covid-19 vaccines and treatments, the anonymised participant level data underlying the trials for these new products remain inaccessible to doctors, researchers, and the public—and are likely to remain that way for years to come.16 This is morally indefensible for all trials, but especially for those involving major public health interventions.

Unacceptable delay

Pfizer’s pivotal covid vaccine trial was funded by the company and designed, run, analysed, and authored by Pfizer employees. The company and the contract research organisations that carried out the trial hold all the data.17 And Pfizer has indicated that it will not begin entertaining requests for trial data until May 2025, 24 months after the primary study completion date, which is listed on ClinicalTrials.gov as 15 May 2023 (NCT04368728).

The lack of access to data is consistent across vaccine manufacturers.16 Moderna says data “may be available … with publication of the final study results in 2022.”18 Datasets will be available “upon request and subject to review once the trial is complete,” which has an estimated primary completion date of 27 October 2022 (NCT04470427).

As of 31 December 2021, AstraZeneca may be ready to entertain requests for data from several of its large phase III trials.19 But actually obtaining data could be slow going. As its website explains, “timelines vary per request and can take up to a year upon full submission of the request.”20

Underlying data for covid-19 therapeutics are similarly hard to find. Published reports of Regeneron’s phase III trial of its monoclonal antibody therapy REGEN-COV flatly state that participant level data will not be made available to others.21 Should the drug be approved (and not just emergency authorised), sharing “will be considered.” For remdesivir, the US National Institutes of Health, which funded the trial, created a new portal to share data (https://accessclinicaldata.niaid.nih.gov/), but the dataset on offer is limited. An accompanying document explains: “The longitudinal data set only contains a small subset of the protocol and statistical analysis plan objectives.”

We are left with publications but no access to the underlying data on reasonable request. This is worrying for trial participants, researchers, clinicians, journal editors, policy makers, and the public. The journals that have published these primary studies may argue that they faced an awkward dilemma, caught between making the summary findings available quickly and upholding the best ethical values that support timely access to underlying data. In our view, there is no dilemma; the anonymised individual participant data from clinical trials must be made available for independent scrutiny.

Journal editors, systematic reviewers, and the writers of clinical practice guideline generally obtain little beyond a journal publication, but regulatory agencies receive far more granular data as part of the regulatory review process. In the words of the European Medicine Agency’s former executive director and senior medical officer, “relying solely on the publications of clinical trials in scientific journals as the basis of healthcare decisions is not a good idea ... Drug regulators have been aware of this limitation for a long time and routinely obtain and assess the full documentation (rather than just publications).”22

Among regulators, the US Food and Drug Administration is believed to receive the most raw data but does not proactively release them. After a freedom of information request to the agency for Pfizer’s vaccine data, the FDA offered to release 500 pages a month, a process that would take decades to complete, arguing in court that publicly releasing data was slow owing to the need to first redact sensitive information.23 This month, however, a judge rejected the FDA’s offer and ordered the data be released at a rate of 55 000 pages a month. The data are to be made available on the requesting organisation’s website (phmpt.org).

In releasing thousands of pages of clinical trial documents, Health Canada and the EMA have also provided a degree of transparency that deserves acknowledgment.2425 Until recently, however, the data remained of limited utility, with copious redactions aimed at protecting trial blinding. But study reports with fewer redactions have been available since September 2021,2425 and missing appendices may be accessible through freedom of information requests.

Even so, anyone looking for participant level datasets may be disappointed because Health Canada and the EMA do not receive or analyse these data, and it remains to be seen how the FDA responds to the court order. Moreover, the FDA is producing data only for Pfizer’s vaccine; other manufacturers’ data cannot be requested until the vaccines are approved, which the Moderna and Johnson & Johnson vaccines are not. Industry, which holds the raw data, is not legally required to honour requests for access from independent researchers.

Like the FDA, and unlike its Canadian and European counterparts, the UK’s regulator—the Medicines and Healthcare Products Regulatory Agency—does not proactively release clinical trial documents, and it has also stopped posting information released in response to freedom of information requests on its website.26

Transparency and trust

As well as access to the underlying data, transparent decision making is essential. Regulators and public health bodies could release details27 such as why vaccine trials were not designed to test efficacy against infection and spread of SARS-CoV-2.28 Had regulators insisted on this outcome, countries would have learnt sooner about the effect of vaccines on transmission and been able to plan accordingly.29

Big pharma is the least trusted industry.30 At least three of the many companies making covid-19 vaccines have past criminal and civil settlements costing them billions of dollars.31 One pleaded guilty to fraud.31 Other companies have no pre-covid track record. Now the covid pandemic has minted many new pharma billionaires, and vaccine manufacturers have reported tens of billions in revenue.32

The BMJ supports vaccination policies based on sound evidence. As the global vaccine rollout continues, it cannot be justifiable or in the best interests of patients and the public that we are left to just trust “in the system,” with the distant hope that the underlying data may become available for independent scrutiny at some point in the future. The same applies to treatments for covid-19. Transparency is the key to building trust and an important route to answering people’s legitimate questions about the efficacy and safety of vaccines and treatments and the clinical and public health policies established for their use.

Twelve years ago we called for the immediate release of raw data from clinical trials.1 We reiterate that call now. Data must be available when trial results are announced, published, or used to justify regulatory decisions. There is no place for wholesale exemptions from good practice during a pandemic. The public has paid for covid-19 vaccines through vast public funding of research, and it is the public that takes on the balance of benefits and harms that accompany vaccination. The public, therefore, has a right and entitlement to those data, as well as to the interrogation of those data by experts.

Pharmaceutical companies are reaping vast profits without adequate independent scrutiny of their scientific claims.33 The purpose of regulators is not to dance to the tune of rich global corporations and enrich them further; it is to protect the health of their populations. We need complete data transparency for all studies, we need it in the public interest, and we need it now.

Footnotes

• Competing interests: We have read and understood BMJ policy on declaration of interests and declare that The BMJ is a co-founder of the AllTrials campaign. PD was one of the Cochrane reviewers studying influenza antivirals beginning in 2009, who campaigned for access to data. He also helped organise the Coalition Advocating for Adequately Licensed Medicines (CAALM), which formally petitioned the FDA to refrain from fully approving any covid-19 vaccine this year (docket FDA-2021-P-0786). PD is also a member of Public Health and Medical Professionals for Transparency, which has sued the FDA to obtain the Pfizer covid-19 vaccine data. The views and opinions do not necessarily reflect the official policy or position of the University of Maryland.

• Provenance and peer review: Commissioned; externally peer reviewed.

Stolen from a well educated person who is also a healthcare professional:

“Among all the vaccines I have known in my life (diphtheria, tetanus, measles, rubella, chickenpox, hepatitis, meningitis and tuberculosis), I want to also add flu and pneumonia. I have never seen a vaccine that forced me to wear a mask and maintain my social distance, even when you are fully vaccinated. I had never heard of a vaccine that spreads the virus even after vaccination.

I had never heard of rewards, discounts, incentives to get vaccinated. I never saw discrimination for those who didn’t. If you haven’t been vaccinated no one has tried to make you feel like a bad person. I have never seen a vaccine that threatens the relationship between family, colleagues and friends. I have never seen a vaccine used to threaten livelihoods, work or school.

I have never seen a vaccine that would allow a 12-year-old to override parental consent.

After all the vaccines I listed above, I have never seen a vaccine like this one, which discriminates, divides and judges society as it is. And as the social fabric tightens… It’s a powerful vaccine! She does all these things except IMMUNIZATION. If we still need a booster dose after we are fully vaccinated, and we still need to get a negative test after we are fully vaccinated, and we still need to wear a mask after we are fully vaccinated, and still be hospitalized after we have been fully vaccinated, it will likely come to “It’s time for us to admit that we’ve been completely deceived.”

I’ve been getting frequent requests for at least the last six months to write about the Novavax covid vaccine. I’ve been resisting, mainly because it’s seemed uncertain whether it would ever actually be approved in the western world. Now that it’s been approved for use in the EU, however, that has changed, and I figure that I can put it off no longer.

I guess the reason so many people are excited about the Novavax vaccine is that it uses a traditional technology that’s been used many times previously, rather than the new-fangled technologies used in the mRNA and adenovector vaccines that have up to now been all that’s available in the US and EU. To many people, that apparently makes it feel inherently safer.

The Novavax vaccine consists of two parts: the Sars-Cov-2 spike protein and an adjuvant (a substance that causes the immune system to realize that a dangerous foreign entity is present, and which thus activates an immune response to the spike protein). So, rather than injecting genetic blueprints in to the body that get cells to make the viral spike protein themselves (as is the case with the four previously approved vaccines), the spike protein is injected directly.

The first country to approve the Novavax vaccine was Indonesia, which approved it for use in November. That means that there is no even slightly long term real world follow-up data available yet. All we have is the preliminary results from the randomized trials. That means we still have no idea about rare side-effects, and won’t for months. Several million people had already received the AstraZeneca vaccine before authorities realized it could cause serious blood clotting disorders, and millions had also received the Moderna and Pfizer vaccines before it became clear that they can cause myocarditis. With that cautionary point having been made, let’s take a look at what the preliminary results from the randomized trials show.

The first trial results concerning the Novavax vaccine appeared in the New England Journal of Medicine in May. 4,387 people in South Africa were randomized to receive either the vaccine or a saline placebo. The trial was conducted during the final months of 2020, when the beta variant was dominant in South Africa. Like the earlier covid vaccine trials, the objective of the study was to understand the ability of the vaccine to prevent symptomatic disease, which was defined as symptoms suggestive of covid-19 plus a positive covid test.

The average age of the participants was 32 years and chronic conditions were rare, so this was a group at low risk of severe disease. When this fact is combined with the relatively small total number of participants (for a vaccine trial), there was no possibility that the study was going to say anything useful about the ability of the vaccine to prevent severe disease. So this was really a trial looking at the ability of the Novavax vaccine to prevent the common cold in healthy young people.

Let’s look at the results.

As with the earlier published vaccine trials, data on efficacy was only provided two months out from receipt of the vaccine. At the two month mark, 15 people in the vaccine group had developed symptomatic covid-19, as compared with 29 people in the placebo group. This gives a relative risk reduction of 49% against the beta variant at two months post vaccination, which is disappointing. It’s below the 50% risk reduction that regulators have set as the minimum level required for them to approve a vaccine.

It’s even more disappointing when you consider that efficacy against symptomatic infection likely peaks at two months out from vaccination, and then drops rapidly – that is the pattern that’s been seen with all the other approved covid vaccines, and it’s very likely that the same is true for this vaccine.

Furthermore, the beta variant is long gone. The other approved vaccines appear to have little to no ability to prevent infection from the currently dominant omicron variant (although they do still seem to reduce the risk of severe disease to a large extent). Here in Sweden you are currently just as likely to get covid regardless of whether you’ve been vaccinated or not, but you’re still far less likely to end up in an ICU due to severe covid if you’ve been vaccinated. There’s no reason to assume that this vaccine is any different.

Let’s move on and look at safety. Safety data was only provided for a sub-set of patients, and for the first 35 days out from receipt of the first vaccine dose. What little there was though, was somewhat discouraging, with twice as many adverse events requiring medical attention in the group receiving the vaccine as in the group receiving the placebo (13 vs 6), and twice as many serious adverse events in the group receiving the vaccine (2 vs 1). To be fair though, the small absolute numbers make it impossible to draw any conclusions about safety based on this limited data. So we’ll wait to pass judgement.

Let’s move on to the second trial, which was published in the New England Journal of Medicine in September. This was a much larger trial than the first, with 15,187 people in the UK who were randomized to either the Novavax vaccine or a saline placebo. Like the earlier study, it was looking at the ability of the vaccine to prevent symptomatic disease. The study ran from late 2020 to early 2021, during a time when the alpha variant was dominant, so the results of the study apply primarily to that variant. 45% of the participants had at least one risk factor that would predispose them to severe disease, and the average age was 56 years.

Ok, so what were the results?

Among participants who received two doses of the vaccine, there were 96 covid infections in the placebo group, but only 10 in the vaccine group during the three month period after receipt of the second dose. This gives an efficacy during the first few months of 90%, similar to what was found in the Moderna and Pfizer vaccine trials. One person ended up being hospitalized for covid-19 in the placebo group, while no-one was hospitalized in the vaccine group – so unfortunately there again weren’t enough hospitalizations to be able to say anything about the ability of the vaccine to prevent severe disease (although it’s pretty clear from this study that even for a relatively high risk group, the overall risk of hospitalization due to covid is low – of 96 people in the placebo group who got covid, only one required hospitalization).

Let’s turn to safety. Safety data is only provided for the period from receipt of the first dose to 28 days out from receipt of the second dose, so we don’t learn anything about the longer term, but at least for that shorter period, there was no signal of serious harm. There were 44 serious adverse events in the vaccine group, and 44 serious adverse events in the placebo group. One person in the vaccine group developed myocarditis three days after receipt of the second dose, which suggests that the Novavax vaccine might cause myocarditis, just like the Pfizer and Moderna vaccines do.

Let’s turn to the final trial, which was published in the New England Journal of Medicine in December. It was carried out in the United States and Mexico during the first half of 2021. Just as with the previous trial, the results apply primarily to the alpha variant. 29,949 participants were randomized to either the Novavax vaccine or a saline placebo. Like the other two trials, the purpose was to see if the vaccine prevented symptomatic disease, again defined as symptoms suggestive of covid-19 plus a positive PCR test. The median age of the participants was 47 years, and 52% had an underlying condition that would predispose them to more severe disease if infected with covid-19.

So, what were the results?

At 70 days out from receipt of the second dose, 0.8% of participants in the placebo group had developed covid-19, compared with only 0.1% in the vaccine group. This gives a relative risk reduction of 90%, a result that is identical to that seen in the previous trial. Unfortunately, no information is provided on hospitalizations, which I assume means that not one of the 29,949 people included in the study was hospitalized for covid-19, so, just as with the earlier trials, it’s impossible to tell if the vaccine results in any meaningful reduction in hospitalizations.

At 28 days post receipt of the seond dose, 0.9% of participants in the vaccine group had suffered a serious adverse event, compared with 1.0% of participants in the placebo group. That is encouraging.

Ok, let’s wrap up. what can we conclude about the Novavax vaccine after looking at the results of these three trials?

First, we can conclude that it effectively protected people from symptomatic covid due to the alpha variant at two-three months post vaccination (which of course tells us nothing about how effective the vaccine is after six months or a year). That information is now mostly of historical interest, since alpha is long gone and we’re living in the era of omicron. If the Novavax vaccine is similar to the four previously approved vaccines, then it’s likely useless at preventing infection due to omicron.

Second, it’s impossible to conclude from these trials whether the Novavax vaccine results in any reduction in risk of hospitalization due to covid, for the simple reason that not enough people ended up being hospitalized. Having said that, my guess would be that it probably does protect against hospitalization and need for ICU treatment, just as the other approved vaccines do. At its heart, it’s doing the same thing as they are – generating an immune response to the spike protein found on the original Wuhan covid variant, and the overall trial results are very similar to the trial results for the Moderna and Pfizer vaccines.

The overall safety data suggests that the vaccine is pretty safe, with serious adverse events being balanced between the vaccine group and the placebo group. Rare side-effects are however not detectable in randomized trials with a few tens of thousands of participants. For that longer term follow-up with much larger numbers of people is necessary. So it’s currently impossible to know whether the Novavax vaccine can cause myocarditis, like the mRNA vaccines, or blood clotting disorders, like the adenovector virus vaccines, or some other type of rare adverse event entirely. It’s therefore impossible to say at the present point in time whether it will turn out to be more safe, or less safe, or equivalent to the already approved vaccines.

In my second week in Saughton jail, a prisoner pushed open the door of my cell and entered during the half hour period when we were unlocked to shower and use the hall telephone in the morning. I very much disliked the intrusion, and there was something in the attitude of the man which annoyed me – wheedling would perhaps be the best description. He asked if I had a bible I could lend him. Anxious to get him out of my cell, I replied no, I did not. He shuffled off.

I immediately started to feel pangs of guilt. I did in fact have a bible, which the chaplain had given me. It was, I worried, a very bad thing to deny religious solace to a man in prison, and I really had no right to act the way I did, based on an irrational distrust. I went off to take a shower, and on the way back to my cell was again accosted by the man.

“If you don’t have a Bible,” he said, “Do you have any other book with thin pages?”

He wanted the paper either to smoke drugs, or more likely to make tabs from a boiled up solution of a drug.

You cannot separate the catastrophic failure of the Scottish penal system – Scotland has the highest jail population per capita in all of Western Europe – from the catastrophic failure of drugs policy in Scotland. 90% of the scores of prisoners I met and spoke with had serious addiction problems. Every one of those was a repeat offender, back in jail, frequently for the sixth, seventh or eighth time. How addiction had led them to jail varied. They stole, often burgled, to feed their addiction. They dealt drugs in order to pay for their own use. They had been involved in violence – frequently domestic – while under the influence.

I had arrived in Saughton jail on Sunday 1 August. After being “seen off” by a crowd of about 80 supporters outside St Leonards police station, I had handed myself in there at 11am, as ordered by the court. The police were expecting me, and had conducted me to a holding area, where my possessions were searched and I was respectfully patted down. The police were very polite. I had been expecting to spend the night in a cell at St Leonards and to be taken to jail in a prison van on the Monday morning. This is what both my lawyers and a number of policemen had explained would happen.

In fact I was only half an hour in St Leonards before being put in a police car and taken to Saughton. This was pretty well unique – the police do not conduct people to prison in Scotland. At no stage was I manacled or handled and the police officers were very friendly. Reception at Saughton prison – where prisoners are not usually admitted on a Sunday – were also very polite, even courteous. None of this is what happens to an ordinary prisoner, and gives the lie to the Scottish government’s claim that I was treated as one.

I was not fingerprinted either in the police station or the jail, on the grounds I was a civil prisoner with no criminal conviction. At reception my overcoat and my electric toothbrush were taken from me, but my other clothing, notebook and book were left with me.

I was then taken to a side office to see a nurse. She asked me to list my medical conditions, which I did, including pulmonary hypertension, anti-phospholipid syndrome, Barrett’s oesophagus, atrial fibrillation, hiatus hernia, dysarthria and a few more. As she typed them in to her computer, options appeared on a dropdown menu for her to select the right one. It was plain to me she had no knowledge of several of these conditions, and certainly no idea how to spell them

The nurse cut me off very bluntly when I politely asked her a question about the management of my heart and blood conditions while in prison, saying someone would be round to see me in the morning. She then took away from me all the prescription medications I had brought with me, saying new ones would be issued by the prison medical services. She also took my pulse oximeter, saying the prison would not permit it, as it had batteries. I said it had been given to me by my consultant cardiologist, but she insisted it was against prison regulations.

This was the most disconcerting encounter so far. I was then walked by three prison officers along an extraordinarily long corridor – hundreds of yards long – with the odd side turning, which we we ignored. At the end of the corridor we reached Glenesk Block. The journey to my cell involved unlocking eight different doors and gates, including my cell door, every one of which was locked behind me. There was no doubt that this was very high security detention.

Once I reached floor 3 of Glenesk block, which houses the admissions wing, we acquired two further guards from the landing, so five people saw me into my cell. This was twelve feet by eight feet. May I suggest that you measure that out in your room? That was to be my world for the next four months. In fact I was to spend 95% of the next four months confined in that space.

The door was hard against one wall, leaving space within the 12 ft by 8 ft cell for a 4 ft by 4 ft toilet in one corner next the door. This was fully walled in, to the ceiling, and closed properly with an internal door. This little room contained a toilet and sink. The toilet had no seat. This was not an accident – I was not permitted a toilet seat, even if I provided it myself. It was a normal UK style toilet, designed to be used with a seat, with the two holes for the seat fixing, and a narrow porcelain rim.

The toilet was filthy. Below the waterline it was stained deep black with odd lumps and ridges. Above the waterline it was streaked and spotted with excrement, as was the rim. The toilet floor was in a disgusting state. The cell itself was dirty with, everywhere a wall or bolted down furniture met the floor, a ridge built up of hardened black dirt.

A female guard looked around the cell, then came back to give me rubber gloves, a surface cleaner spray and some cloths. So I spent my first few hours in my cell on my knees, scrubbing away furiously with these inadequate materials.

The female guard had advised me that even after cleaning the cell I should always keep shoes on, because of the mice. I heard them most nights in my cell, but never saw one. The prisoners universally claim them to be rats, but not having seen one I cannot say.

A guard later explained to me that prisoners are responsible for cleaning their own cells, but as nobody generally stayed in a new admissions cell for more than two or three nights, nobody bothered. Cells for new arrivals will be cleaned out by a prisoner work detail, but as I had arrived on a Sunday, that had not happened.

So about 3pm I was locked in the cell. At 5.20pm the door opened for two seconds to check I was still there, but that was it for the day. There I was confused, disoriented and struggling to take in that all this was really happening. I should describe the rest of the cell.

A narrow bed ran down one wall. I came to realise that prison in Scotland still includes an element of corporal punishment, in that the prisoner is very deliberately made physically uncomfortable. Not having a toilet seat is part of this, and so is the bed. It consists of an iron frame bolted to the floor and holding up a flat steel plate, completely unsprung. On this unyielding steel surface there is a mattress consisting simply of two inches of low grade foam – think cheap bath sponge – encased in a shiny red plastic cover, slashed or burnt through in several places and with the colour worn off down the centre.

The mattress was stamped with the date 2013 and had lost its structural resistance, to the extent that if I pinched it between my finger and thumb, I could compress it down to a millimetre. On the steel plate, this mattress had almost no effect and I woke up after a sleepless first night with acute pain throughout my muscles and difficulty walking. To repeat, this is deliberate corporal punishment – a massively superior mattress could be provided for about £30 more per prisoner, while in no way being luxurious. The beds and mattresses can only be designed to inflict both pain and, perhaps more important, humiliation. It is plainly quite deliberate policy.

It is emblematic of the extraordinary lack of intellectual consistency in the Scottish prisons system that cells are equipped with these Victorian punishment beds but also with TV sets showing 23 channels including two Sky subscription channels (of which I shall write more in another instalment). The bed is fixed along one long wall, while a twelve inch plywood shelf runs the length of the other and can serve as a desk. At one end, up against the wall of the toilet, this desk meets a built-in plywood shelving unit fixed into the floor, on top of which are sat the television and kettle next to two power points. At the other end of the desk, a further set of shelves are attached to the wall above. There is a plastic stackable chair of the cheapest kind – the sort you see stacked outside poundshops as garden furniture.

On the outside wall there is a small double glazed window with heavy, square iron bars two inches thick running both horizontally and vertically, like a noughts and crosses grid. The window does not open, but had metal ventilation strips down each side, which were stuck firmly closed with black grime. At the other end of the cell, next to the toilet, the heavy steel door is hinged so as to have a distinct gap all round between the door and the steel frame, like a toilet cubicle door.

Above the desk shelf is fixed a noticeboard, which is the only place prisoners are allowed to put up posters or photos. However as prisoners are not permitted drawing pins, staples, sellotape or blu tak, this was not possible. I asked advice from the guards who suggested I try toothpaste. I did – it didn’t work.

There is a single neon light tube.

The admissions unit has single-occupancy cells, of which there are very few in the rest of the jail. All the prison’s cells were designed for single occupancy, but massive overcrowding means that they are mostly in practice identical to this description, but with a bunk bed rather than a single bed.

The prison is divided into a number of blocks. Glenesk block had three floors, each containing 44 of these cells. Each floor is entered by a central staircase and has a centrally located desk where the guards are stationed. Either side of the desk are two heavy metal grills stretching right across the floor and dividing it into two wings. Within the central area is the kitchen where meals are collected (though not prepared), then eaten back locked in the cell.

The corridor between the cells either side of each wing is about 30 feet wide. It contains a pool table and fixed chairs and tables, and is conceived as a recreational area. There are two telephones at the end of each wing from which prisoners may call (at 10p a minute) numbers from a list they have pre-registered for approval.

The various cell blocks are located off that central spine corridor whose length astonished me at first admission. I did not realise then that this is a discreet building in itself rather than a corridor inside a building – it is like a long concrete overground tunnel.

I should describe my typical day the first ten weeks. At 7.30am the cell door springs open without warning as guards do a head count. The door is immediately locked again. At 8am cereals, milk and morning rolls are handed in, and the door is immediately locked again. At 10am I was released into the corridor for 30 minutes to shower and use the telephone. The showers are in an open room but with individual cubicles, contrary to prison movie cliche. At 10.30am I was locked in again.

At 11am I was released for one hour and escorted under supervision to plod around an enclosed, tarmac exercise yard about 40 paces by 20 paces. This yard is filthy and contains prison bins. One wing of Glenesk block forms one side, and the central spine corridor forms another; the wall of a branch corridor leading to another cell block forms a third and a fence dividing off that block a fourth. The walls are about 10 feet high and the fence about 16 feet high.

In the non-admissions, larger area of Glenesk block the cells had windows with opening narrow side panels. It is the culture of the prison that rather than keep rubbish in their cells and empty it out at shower time, the prisoners throw all rubbish out of their cell windows into the exercise yard. This includes food waste and plates, newspapers, used tissues and worse. At meal times, sundry items (bread, margarine etc) are available on a table outside the kitchen and some prisoners scoop up quantities simply to throw them out of the window into the yard.

I believe the origin of this is that this enclosed yard is used by protected prisoners, many of whom are sexual offenders. Glenesk house has a protected prisoner area on its second floor. “Mainstream” prisoners from Glenesk exercise on the astroturf five-a-side football pitch the other side of the spine corridor. (For four months that pitch was the view from my window and I never saw a game of football played. After three months the goals were removed.) New admissions exercise in the protected yard because they have not been sorted yet – that sorting is the purpose of the new admissions wing. New prisoners therefore have to plough through the filth prepared for protected prisoners.

At times large parts of this already small exercise yard were ankle deep in dross – it was cleaned out intermittently, probably on average every three weeks. Only on a couple of occasions was it so bad I decided against exercise. After exercise getting the sludge off my shoes as we went straight back to my cell was a concern. I now understood how the cell had got so dirty.

After exercise, at noon I collected my lunch and was locked back in the cell. Apart from 2 minutes to collect my tea, I would be locked in from noon until 10am the following morning, for 22 hours solid, every single day. In total I was locked in for 22 and a half hours a day for the first ten weeks. After that I was locked in my cell for 23 hours and 15 minutes a day due to a covid outbreak.

At 5pm the door would open for a final headcount, and then we would be on lockdown for the night, though in truth we had been locked down all day. Lockdown here meant the guards were going home.

Now I want you again to just mark out twelve feet by eight feet on your floor and put yourself inside it. Then imagine being confined inside that space a minimum of 22 and a half hours a day. For four months. These conditions were not peculiar to me – it is how all prisoners were living and are still living today. The library, gym and all educational activities had been closed “because of covid”. The resulting conditions are inhumane – few people would keep a dog like that.

It is also worth noting that Covid is an excuse. In September 2017 an official inspection report already noted that significant numbers of prisoners in Saughton were confined to cells for 22 hours a day. The root problem is massive overcrowding, and I shall write further on the causes of that in a future instalment.

The long concrete and steel corridors of the prison echo horribly, and after lockdown for the first time I felt rather scared. All round me prisoners were shouting out at the top of their voices. That first evening two were yelling death threats at another prisoner, with extreme expressions of hate and retribution. Inter-prisoner communication is by yelling out the window. This went on all night into the early hours of the morning. Prisoners were banging continually on the steel doors, sometimes for hours, calling out for guards who were not there. Somebody was crying out as though being attacked and in pain. There were sounds of plywood splintering as people smashed up their rooms.

It was unnerving because it seemed to me I was living amongst severely violent and out of control berserkers.

Part of the explanation of this is that for most prisoners the new admissions wing on first night is where they go through withdrawal symptoms. Many prisoners come in still drugged up. They are going through their private hell and desperate to get medication. I can understand (though not condone) why the prison medical staff are so remarkably bad and unhelpful. Their job and circumstances are very difficult.

On that first evening I was concerned that I did not have my daily medicines, and by the next morning my heart was getting distinctly out of synch. I was therefore relieved to receive the promised medical visit.

My cell door was opened and a nurse, flanked by two guards, addressed me from outside my cell. She asked if I had any addictions. I replied in the negative. I asked when I might receive my medicines. She said it was in process. I asked if I might get my pulse oximeter. She said the prison did not allow devices with batteries. I asked if my bed could somehow be propped or sloped because of my hiatus hernia (leading to gastric reflux) and Barrett’s oesophagus. She said she didn’t think that the prison could do that. I asked about management of my blood condition (APS), saying I was supposed to exercise regularly and not sit for long periods. She replied by asking if I would like to see the psychiatric team. I replied no. She left.

I was taken out to exercise alone, with four guards watching me. I felt like Rudolf Hess. In the lunch queue I met my first prisoners, who were respectful and polite. The day passed much as the first, and I still did not get my medicines on the Monday. They arrived on the Tuesday morning, as did the prison governor.

I was told the governor had come to see me, and I met him in the (closed) Glenesk library. David Abernethy is a taciturn man who looks like a rugby prop and has a reputation among prisoners as a disciplinarian, compared to other prison regimes in Scotland. He was accompanied by John Morrison, Glenesk block manager, a friendly Ulsterman, who did most of the talking.

I was an anomaly in that Saughton did not normally hold civil prisoners. The Governor told me he believed I was their first civil prisoner in four years, and before that in ten. Civil prisoners should be held separately from criminal prisoners, but Saughton had no provision for that. The available alternatives were these: I could move into general prisoner population, which would probably involve sharing a cell; I could join the protected prisoners; or I could stay where I was on admissions.

On the grounds that nothing too terrible had happened to me yet, I decided to stay where I was and serve my sentence on admissions.

They wished to make plain to me that it was their job to hold me and it was not for them to make any comment on the circumstances that brought me to jail. I told them I held no grudge against them and had no reason to complain of any of the prison officers who had (truthfully) so far all been very polite and friendly to me. I asked whether I could have books I was using for research brought to me from my library at home; I understood this was not normally allowed. I was also likely to receive many books sent by well-wishers. The governor said he would consider this. They also instructed, at my request, extra pillows to be brought to prop up the head of my bed due to my hiatus hernia.

That afternoon a guard came along (I am not going to give the names except for senior management, as the guards might not wish it) with the pillows, and said he had been instructed I was a VIP prisoner and should be looked after. I replied I was not a VIP, but was a civil prisoner, and therefore had different rights to other prisoners.

He said that the landing guards suggested that I should take my exercise and shower/phone time at the same time as other mainstream new admission prisoners (sexual offender and otherwise protected new admission prisoners had separate times). I had so far been kept entirely apart, but perhaps I would prefer to meet people? I said I would prefer that.

So the next day I took my exercise in that filthy yard in the company of four other prisoners, all new arrivals the night before. I thus observed for the first time something which astonished me. Once in the yard, the new prisoners (who on this occasion arrived individually, not all part of the same case), immediately started to call out to the windows of Glenesk block, shouting out for friends.

“Hey, Jimmy! Jimmy! It’s me Joe! I am back. Is Paul still in? What’s that? Gone tae Dumfries? Donnie’s come in? That’s brilliant.”

The realisation dropped, to be reinforced every day, that Saughton jail is a community, a community where the large majority of the prisoners all know each other. That does not mean they all like each other – there are rival gangs, and enmities. But prison is a routine event in not just their lives, but the lives of their wider communities. Those communities are the areas of deprivation of Edinburgh.

Edinburgh is a city of astonishing social inequality. It contains many of the areas in the bottom 10% of multiple social deprivation in Scotland (dark red on the map below). These are often a very short walk from areas of great affluence in the top 10% (dark blue on the map). Of course, few people make that walk. But I recommend a spell in Saughton jail to any other middle class person who, like myself, was foolish enough to believe that Scotland is a socially progressive country.

The vast majority of prisoners I met came from the red areas on these maps. The same places came up again and again – including Granton, Pllton, Oxgangs, Muirhouse, Lochend, and from West Lothian, Livingston and Craigshill. Saughton jail is simply where Edinburgh locks away 900 of its poorest people, who were born into extreme poverty and often born into addiction. Many had parents and grandparents also in Saughton jail.

A large number of prisoners have known institutionalisation throughout their lives; council care and foster homes leading to young offenders’ institutions and then prison. A surprising number have very poor reading and writing skills. The overcrowding of our prisons is a symptom not just of failed justice and penal policy, but of fundamentally flawed economic, social and educational systems.

Of which I shall also write more later. Here, on this first day with a group in the exercise yard, I was mystified as the prisoners started going up to the ground floor windows and the guards started shouting “keep away from the windows! Stand back from the windows” in a very agitated fashion, but to no effect. Eventually they removed one man and sent him back to his cell, though he seemed no more guilty than the others.

By the next week I had learnt what was happening. At exercise the new admissions prisoners get drugs passed to them through the window by their friends who have been in the prison longer and had time to get their supply established. These drugs are passed as paper tabs, as pills or in vape tubes. There appears no practical difficulty at all in prisoners getting supplied with plentiful drugs in Saughton. Every single day I was to witness new admissions prisoners getting their drugs at the window from friends, and every single day I witnessed this curious charade of guards shouting and pretending to try and stop them.

My first few days in Saughton had introduced me to an unknown, and sometimes frightening, world, of which I shall be telling you more.

For months now, I’ve been getting complaints about the Canadian Broadcasting Corporation, where I’ve worked as a TV and radio producer, and occasional on-air columnist, for much of the past decade.

People want to know why, for example, non-binary Filipinos concerned about a lack of LGBT terms in Tagalog is an editorial priority for the CBC, when local issues of broad concern go unreported. Or why our pop culture radio show’s coverage of the Dave Chappelle Netflix special failed to include any of the legions of fans, or comics, that did not find it offensive. Or why, exactly, taxpayers should be funding articles that scold Canadians for using words such as “brainstorm” and “lame.”

Everyone asks the same thing: What is going on at the CBC?

When I started at the national public broadcaster in 2013, the network produced some of the best journalism in the country. By the time I resigned last month, it embodied some of the worst trends in mainstream media. In a short period of time, the CBC went from being a trusted source of news to churning out clickbait that reads like a parody of the student press.

Those of us on the inside know just how swiftly — and how dramatically — the politics of the public broadcaster have shifted.

It used to be that I was the one furthest to the left in any newsroom, occasionally causing strain in story meetings with my views on issues like the housing crisis. I am now easily the most conservative, frequently sparking tension by questioning identity politics. This happened in the span of about 18 months. My own politics did not change.

To work at the CBC in the current climate is to embrace cognitive dissonance and to abandon journalistic integrity.

It is to sign on, enthusiastically, to a radical political agenda that originated on Ivy League campuses in the United States and spread through American social media platforms that monetize outrage and stoke societal divisions. It is to pretend that the “woke” worldview is near universal — even if it is far from popular with those you know, and speak to, and interview, and read.

To work at the CBC now is to accept the idea that race is the most significant thing about a person, and that some races are more relevant to the public conversation than others. It is, in my newsroom, to fill out racial profile forms for every guest you book; to actively book more people of some races and less of others.

To work at the CBC is to submit to job interviews that are not about qualifications or experience — but instead demand the parroting of orthodoxies, the demonstration of fealty to dogma.

It is to become less adversarial to government and corporations and more hostile to ordinary people with ideas that Twitter doesn’t like.

It is to endlessly document microaggressions but pay little attention to evictions; to spotlight company’s political platitudes but have little interest in wages or working conditions. It is to allow sweeping societal changes like lockdowns, vaccine mandates, and school closures to roll out — with little debate. To see billionaires amass extraordinary wealth and bureaucrats amass enormous power — with little scrutiny. And to watch the most vulnerable among us die of drug overdoses — with little comment.

It is to consent to the idea that a growing list of subjects are off the table, that dialogue itself can be harmful. That the big issues of our time are all already settled.

It is to capitulate to certainty, to shut down critical thinking, to stamp out curiosity. To keep one’s mouth shut, to not ask questions, to not rock the boat.

This, while the world burns.

How could good journalism possibly be done under such conditions? How could any of this possibly be healthy for society?

All of this raises larger questions about the direction that North America is headed. Questions about this new moment we are living through — and its impact on the body politic. On class divisions, and economic inequality. On education. On mental health. On literature, and comedy. On science. On liberalism, and democracy.

These questions keep me up at night.

I can no longer push them down. I will no longer hold them back. This Substack is an attempt to find some answers.

I have been a journalist for 20 years, covering everything from hip-hop to news, food to current affairs. The through line has always been books, which I’ve engaged with at every stage of my career and at every outlet I’ve worked for. In 2020, I published my own book, Lean Out: A Meditation on the Madness of Modern Life, which was an instant bestseller in Canada.

Books have always opened new worlds for me, introduced me to new perspectives, and helped me to make sense of humanity. I need books now more than ever.

During lockdown, when I wasn’t covering COVID-19, I spent a lot of time interviewing authors for a new book I’m working on. Their boldness and insight and humour saved me from despair. These writers gave me ideas on how to move forward, and how to maintain hope. Most of all, they gave me the courage to stand up — and to speak out.

There are many things we can do to liberate ourselves, and each other, from the tyranny of government. Unfortunately, for generations, we have been educated to believe we are powerless. Supposedly our voice can only be heard through the ballot box, our extremely limited ability to lobby and whatever protests we are allowed.

This is a deception. We have all the power, government has none and we can change the world whenever we choose.

All we need to do is realise our collective agency and strength. The good news is that, if we consistently work toward freedom, achieving it is a nailed on certainty. The bad news is that very few of us are even aware of the need to change our behaviour and fewer still know how to do it.

Our broad lack of awareness leaves us at the mercy of those who do understand how to misuse behaviour change techniques and applied psychology for nefarious purposes. This mistreatment has led a sizeable minority to rail against applied behavioural psychology. Yet, should we decide the use these strategies ourselves, the potential for positive social change is immense.

This article is written in the hope that we can all learn how use behaviour change techniques for our benefit. Behaviour change is a skill that can be learned and, with practice, become a powerful tool for personal development. We can use it to defeat the plans of those who would use it against us and construct a free society.

The Misuse Problem

Over the last two years we have experienced, and are continuing to endure, a global behavioural change programme designed to force us into compliance. Psychological operations (psyops) have been used to adapt our behaviour to a so-called “new normal.” One of the objective is to condition us to respond automatically to an announced crisis, whatever it may be, and to obey government commands.

This isn’t a contentious point. Applied behavioural change techniques are common practice at both the world governance and national government level. The World Health Organisation outline how they interpret their use:

A health campaign follows a specific sequence that moves the target audience from awareness of an issue towards a behaviour resulting in a specific health outcome […] Presenting a consistent message from multiple sources increases the likelihood of action […] Trusted messengers and high-profile personalities can add their voices to the campaign.

In February 2020, one month before they declared a global pandemic, the WHO announced the creation of its Technical Advisory Group on Behavioural Insights and Sciences for Health (TAG). The group is chaired by Prof. Cass Sunstein and its members include behavioural change experts from the World Bank, the World Economic Forum and the Bill and Melinda Gates Foundation. Prof. Susan Michie, from the UK, is also a TAG participant.

Cass Sunstein co-authored a 2008 paper titled Conspiracy Theories in which he and Prof. Adrian Vermeule advocated a series of psychological methods to counter the arguments of people who doubt official narratives. Sunstein & Vermeule ruled out engaging in logical, evidence based debate. Instead, they proposed a concerted psyop campaign to discredit anyone who questioned the government.

TAG soon published Principles and Steps for Applying a Behavioural Perspective to Public Health in which they identified six principles they would utilise. Deciding that knowledge was “often not enough to change behaviours,” TAG implemented a different methodology. Noting that the behavioural choices we make are “influenced by the environment in which an individual resides and makes decisions,” TAG concluded:

Approaching public health from a behavioural perspective requires focusing on people and their behaviours in the context in which those behaviours occur […] Behaviours can be defined so that the influences on those behaviours in terms of barriers and drivers can be diagnosed. The strategies and interventions that can change those behaviours can then be designed.

There was no mention of consent anywhere in the document. TAG advocate manipulation of the context in which behaviours occur. This enables them to design the behavioural response. We are the subjects of their efforts and TAG don’t consider either our knowledge or consent to be relevant.

Susan Michie is also a member of the UK government’s Scientific Advisory Group for Emergencies (SAGE). They have provided much of the “evidence” which the UK government used to justify its anti-scientific response to the pseudopandemic. Michie is also a leading member of the SAGE behavioural change subgroup, Spi-B.

Like her fellow TAG and Spi-B behavioural change experts, Michie favours psyops over logical discourse. In an advisory report, dated 22nd March 2020, SPi-B recommended that the UK government engage in a media led terror campaign to coerce the public into pseudopandemic compliance:

A substantial number of people still do not feel sufficiently personally threatened […] The perceived level of personal threat needs to be increased among those who are complacent, using hard-hitting emotional messaging […] Some people will be more persuaded by appeals to play by the rules, some by duty to the community, and some to personal risk. All these different approaches are needed […] Use media to increase sense of personal threat […] Consider use of social disapproval for failure to comply.

Government in the UK, and elsewhere, deployed precisely this methodology with the assistance of their mainstream media partners. This was a continuation of the manipulation proposed in the UK governments 2010 document called MINDSPACE. The report outlined how government could misuse behaviour change for propaganda and compliance purposes.

It stressed the importance of avoiding any discussion of the evidence and focused upon overcoming peoples’ rational minds using psychological manipulation. Notably, this could be achieved without the subjects (us) even being aware that we were effectively being programmed:

People’s behaviour may be altered if they are first exposed to certain sights, words or sensations […] people behave differently if they have been ‘primed’ by certain cues beforehand.. Emotional responses to words, images and events can be rapid and automatic.. people can experience a behavioural reaction before they realise what they are reacting to […] This shifts the focus of attention away from facts and information, and towards altering the context within which people act […] Behavioural approaches embody a line of thinking that moves from the idea of an autonomous individual, making rational decisions, to a ‘situated’ decision-maker, much of whose behaviour is automatic and influenced by their choice environment […] citizens may not fully realise that their behaviour is being changed – or, at least, how it is being changed.

This approach utilises the covert psychological strategies suggested by Sunstein two years earlier. Spi-B and TAG were among those who exploited them throughout the pseudopandemic. Combined with wide reaching censorship and a concerted media propaganda campaign, the objective was to hide or otherwise obfuscate evidence and move people away from rationality towards becoming “situated decision makers.”

Programmed to accept a tightly defined set of limited discussion points, people were coerced into believing in a predetermined “choice environment.” The context and extent of their decision making was thus controlled, leaving many subjects psychologically disabled. Once the choice environment had been established, behavioural responses could then be designed without any resistance from the situated decision makers.

This form of brainwashing primarily targets the subconscious. It is highly effective because it leaves the subject imagining they have free choice or free will. This deception renders us far more likely to behave as instructed. However, in reality, our behavioural options are restricted to the desired outcomes only. The behavioural commitment of the subject is engineered by their situated position within the choice environment.

The misuse of behavioural change techniques, and the applied psychology that underpins them, is totally unethical. It is a form of psychological abuse that was and is still inflicted upon the global population to push an agenda.

In the UK this prompted a concerned group of psychologists and therapists to write to the British Psychological Society (BPS), urging them to investigate the abuse and issue a statement. Eventually the BPS replied with what many considered to be an evasive, disingenuous and wholly unconvincing reponse.

Given the activities of TAG, Spi-B and others, strong opposition to this psychological manipulation by government is understandable. It is essential that we draw a distinction between their covert, unethical misuse of behavioural change and the appropriate use of these strategies.

Used as part of talking therapy, behaviour change (or modification) is perhaps the most powerful technique for the treatment of many unwanted, self-destructive behaviours. It has helped millions of people around the world overcome addiction and provides us with tools we can use in our daily lives to achieve a wide range of goals and objectives.

For example, if freedom is our aim, we can use the skills we learn from Acceptance and Commitment Therapy (ACT) to live as free, sovereign human beings. If enough of us do so it is inevitable that we will create the free society most of us want. We do not have to live under the tyrannical oppression of any government that seeks to control us through brainwashing and fear.

Acceptance And Commitment Therapy (ACT)

Acceptance And Commitment Therapy (ACT) helps us to notice the thoughts and experiences that lead us to adopt potentially destructive behaviours. Once we have acknowledged and accepted the reality of our current condition we can identify the associated behaviours, develop better coping strategies and commit to behavioural change.

We can use the ACT matrix as a mental map to guide us away from damaging or life-limiting behaviours and instead actively choose behaviour that moves us closer to our goal. This is depicted below and the the diagram can be carried on the person as an aide-mémoire. However, once people are familiar with applying ACT in their daily lives, the simplicity of the model allows most to visualise it when needed.

Acceptance and Commitment Therapy Matrix

Each of us perceive the world through our senses. This enables us to build a mental picture of reality. However, thoughts, emotions and physical sensations can impact upon our perception.

Take, for example, a forest walk. The sights, sounds, smells, textures and even tastes form our appreciation of nature and the experience. However, if we start to feel the uncomfortable sensation of substance withdrawal then, despite the evidence of our senses, we can perceive the forest as little more than a dark prison stopping us from getting to the substance we desire.

Our mental experience does not necessarily reflect reality. Other “unwanted stuff,” such as cravings or fear, often get in the way. When they do we can easily become “situated decision makers.”

Unable to cope with our internal conflicts, we often resort to behaviours that are driven by these unwanted thoughts, emotions, physical sensations or beliefs. We respond to them instead of the present reality of our environment or condition.

These behaviours, such as problematic substance use, can be fatal. The behaviours themselves can compound the unwanted thoughts, emotions, and physical sensations. We may enter the cycle of addiction where physical changes and altered brain function can occur, further compelling the destructive behaviour.

ACT teaches us that the first thing we need to do is pay attention to the here and now. Our reality is formed through both physical and psychological influences and we need to be “mindful” of both. The ability to root ourselves in awareness of the ‘here and now’ can be improved by practising mindfulness exercises.

The objective is not to sit in mindful contemplation but to improve self-awareness skills. Our capacity to focus upon what is happening to us in any given moment will afford us self-control.

For example, we might improve our awareness of the conflict between the tranquillity of a forest walk and our craving for a drug. Both can perceived simultaneously. The craving is an uncomfortable sensation but that does not need to alter our comprehension of the forest.

We are able to identify the difference between external reality and internal distress. In this awareness we can start to address the resultant behaviour that is driven by our personal experience, not the forest. We can no longer blame the forest (our environment or other people) for actions that are our own responsibility.

The next step in ACT is acceptance. It is pointless pretending that we are not experiencing cravings, emotional distress or physical pain when, in reality, we are. Trying to deny these experiences, whether psychosomatic or caused directly by physical stimuli, simply increases our anxiety, often heightening our discomfort.

If we accept what is happening to us we can confront it. If we deny it we never will.

When we don’t pay attention to the – here and now – it is very easy for us to automatically adopt learned behaviours based upon misconceptions. Especially if we use them as coping strategies whenever we encounter a trigger. Noticing is the key to unlocking behavioural control.

Let’s say we cope with stress by drinking alcohol. Every time we are in a stressful situation we increase the chance of drinking more because we wrongly believe that is our only option or that the behaviour carries no risk. For most people this isn’t a problem but for many it can become life threatening. If stress is a trigger, ACT teaches problematic drinkers to notice what causes them stress and the signs of being stressed as they emerge.

Once able to recognise the risk, as it occurs, the problematic drinker has an awareness of behavioural choice. They can rely upon a behaviour which they know to be harmful or they can use a different coping strategy that is less harmful or hopefully causes no harm at all.

ACT is about awareness of reality. If drinking chills you out, in the moment, then whatever behaviour you choose to use as a coping strategy also has to work. Otherwise it isn’t a real choice. Someone who is alcohol dependent, following detox and in recovery, may choose to listen to music, exercise, read, pray or cook instead of drinking. Whatever behaviour they use, all that matters is that it works and moves them towards their chosen goal.

ACT empowers people to gain control over behaviour that can either move them away or toward what is important to them. They do this through commitment to behavioural control. However, just as ACT demands that behavioural choice is real, so it requires a genuine appraisal of what matters to us.

Perhaps substance misuse has broken relationships, led to health problems or endangered the individual by repeatedly placing them in high risk situations. It is pointless pretending that relationships, health or safety matter more than using or drinking if that is not true. There is little chance of you moving away from harmful behaviour if you have nothing better to move toward.

For many people who use ACT this is perhaps the most challenging aspect. The moment they accept that their self-destructive or damaging behaviour matters more to them than anything else in the world can be an extremely painful realisation. It may be the first time they have truly confronted the stark reality of their problem.

This is a very high risk moment in the recovery journey. Relapse into self-destructive behaviour is a strong possibility.

ACT requires hard work and commitment. Hopefully, with the support of a decent therapist or psychologist, the individual can be afforded the safest possible opportunity to revaluate their life. This is no easy thing to do, as anyone who has been through it will attest. The majority are able to be honest with others most of the time, yet we struggle to be honest with ourselves.

Once this work is complete most people realise that their problematic behaviour is harming them and choose to readjust their priorities. They can set a goal that is truly more important to them than their problematic behaviour. It doesn’t really matter what this is. It could be rebuilding family relationships, health, safety, career, pets or, especially for those whose behaviour has led them into the judicial system, a commitment to freedom.

Every moment if filled with behaviour. Behaviour can lead us either away or toward what is important to us. ACT empowers individuals to recognise the risks inherent to the instance of behavioural choice. Rather than automatically responding as situated decision makers they can use the tools they have acquired to regain their autonomy and make rational behavioural decisions based upon their knowledge, values and objectives.

How to Use ACT To Free The World

In light of the activities of TAG and Spi-B and other institutions, we must confront the reality that we have governments that do not serve us. They merely play a policy enforcement role in a worldwide network we can call the Global Public-Private Partnership (G3P).

Government serves the G3P, not us. They use covert brainwashing techniques to control us. Our behaviour is “designed” and we are not free.

Click The Image To Expand

The obvious deceit and disinformation that characterises the G3P’s pseudopandemic has led an increasing number of people to recognise the tyranny of our governments. They can now see that government seeks to control every aspect of our lives on behalf of their G3P partners.

While governments around the world are busy back-pedalling on their outlandish claims, it won’t be long before they roll-out the next fear inducing psyop. This problem will permanently remain unless we do something about it.

From censoring the Internet to attempting to ban all protest, forcing people to take drugs they don’t want, surreptitiously deceiving us into accepting digital identities, that we have consistently rejected in the past, and removing our so-called human rights whenever convenient, it is pretty clear that alleged representative democracy is being replaced by dictatorship.

We imagine that the only way to change government is to elect, lobby or protest. But the problem is not the political parties who form government, although the party political system is a problem in and of itself, it is that whoever forms government serves the G3P regardless. Voting won’t change that. No one elects the people who lead the G3P’s compartmentalised, authoritarian structure.

Faced with a global network of multinational corporations, governments, NGO’s, philanthropic foundations and a mainstream media industrial complex propaganda machine, who are also part of the G3P, it can feel like we are powerless to resist. However, this is itself an illusion.

The truth is that the whole apparatus of state has been created to oppress us precisely because those who benefit from it realise that they are ultimately powerless. If we collectively decide to act, while the G3P partners will fight to retain their authority, they cannot win.

All we need to do is take action as individuals. When enough of us do we will change the world. It is inevitable.

Protest, legal challenges, lobbying, sharing information and campaigning on issues we care about are all valuable if we want to be free but, in order to change the world, what we really need to do is change our own behaviour. Instead of doing the things that move us away from freedom we need to consistently do the things that move us toward it.

Though often misquoted, Mahatma Gandhi explained this process eloquently:

We but mirror the world. All the tendencies present in the outer world are to be found in the world of our body. If we could change ourselves, the tendencies in the world would also change. As a man changes his own nature, so does the attitude of the world change towards him.

We can make this change by using ACT. If freedom is what matters to us then we must persistently behave in a way that moves us toward it. Equally, we must stop behaving in a way that moves us away from freedom.

This requires that we notice what is happening in the here and now. Is there a difference between our thoughts, feelings and emotions and reality?

We may notice that everyone around us is wearing a mask, reinforcing the visual cues suggesting a danger. Fear could be the emotion that is driving our behaviour. We must accept both the physical reality of our environment and the psychological state of fear we may be in.

Understanding the “here and now” and armed with ACT principles, we can overcome our fear and commit to what is important to us in that moment. We must ask ourselves which direction our behaviour will, not may, lead us. We have a behavioural choice and if we want to reach our goal, we must act accordingly.

If we choose to behave in a way that moves us away from freedom then we will eventually lose our freedoms and move closer to tyranny. If we choose to behave in a way that moves us towards freedom then we will be one step closer to it. The cumulative effect of all these behavioural choices will either be freedom or tyranny.

We have previously discussed the kind of solutions we might pursue. With these in mind, we can use ACT to steadily move towards freedom.

We know that the G3P intend to introduce Central Bank Digital Currency (CBDC). It is no coincidence that the pseudopandemic has been very helpful in further reducing our use of cash. CBDC is planned to be a liability of the central banks. When it is introduced it will be their money and never ours.

It is also programmable money, meaning that individual transaction can be monitored and controlled by the central bank. You will no longer be free to choose what you buy or who you transact with. A CBDC world represents nothing less than total, global monetary slavery.

The disappearance of cash will more easily facilitate the introduction of CBDC. Therefore, if freedom is important to us, we must not let cash disappear. In fact, we need to make cash indispensable to businesses across the world.

Using ACT, whenever we make a purchase or transaction we must ask ourselves if our behaviour moves us towards or away from freedom. While it is not always possible to use cash but, wherever and whenever it is, if we want to move towards freedom, we must use cash. If a store refuses to accept cash then don’t frequent it, choose one that does. Doing so will move us towards freedom.

We have been subjected to an unprecedented mainstream media propaganda campaign. Paying your TV license or buying mainstream media rags moves us away from freedom. So, using ACT, consider what other behavioural options would better suit your objective. If you need to be updated with current affairs, choose alternative media or free online sources.

If you choose to support the independent media you will be moving toward freedom. You will probably be better informed and will move away from tyranny.

Use ACT to move toward freedom by considering where you buy goods and services. If you simply give your hard earned money to multinational corporations does that move you away or toward freedom? If it moves you away, don’t do it.

Instead give it to local traders and small businesses, or barter and exchange wherever possible. This maintains and increases choice and is a step toward freedom.

The G3P agenda is to centralise all authority at a global level. Centralisation of authority moves us away from freedom. Therefore, don’t simply obey the edicts of global authority. If it is possible to disobey then always disobey on principle. This moves us towards freedom and away from tyranny.

There are a never ending list of behavioural choices that we make every day that can either move us away from or towards freedom. If freedom matters and we persistently make those choices with regard to “what is important to us,” we will create the demand for freedom. If we do it in sufficient numbers that demand will be overwhelming and it will ensure that we live in freedom.

It is not going to be easy. It will be far less convenient and require more effort than simply going with the flow. But relying on behaviours that move us towards tyranny will assuredly lead us into tyranny. It cannot be otherwise.

It all comes down to what you believe and what is important to you. If you value freedom then you must actively choose the behaviour that leads you to freedom.

Once you are familiar with behavioural change principles, using them can quickly become second nature. While constantly checking your own behaviour can feel cumbersome or even irritating to begin with, stick with it.

In no time at all you will largely control your behaviour and will forge a path towards freedom. Not only can we build a society based upon the principles of freedom, if we each take personal responsibility for our behaviour, we will build it.

1. Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/

2. Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1052305721003414

3. Fatal cerebral hemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/

4. Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: https://www.sciencedirect.com/science/article/pii/S2666602221000409

5. Three cases of acute venous thromboembolism in women after vaccination against COVID-19: https://www.sciencedirect.com/science/article/pii/S2213333X21003929

6. Acute thrombosis of the coronary tree after vaccination against COVID-19: https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988

7. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: https://pubmed.ncbi.nlm.nih.gov/33929487/

8. Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/

9. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/

10. Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: https://www.sciencedirect.com/science/article/pii/S0022510X21003014

11. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381

12. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505

13. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904

14. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: https://www.sciencedirect.com/science/article/pii/S1665268121000557

15. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): https://www.sciencedirect.com/science/article/pii/S1050173821000967

16. Roots of autoimmunity of thrombotic events after COVID-19 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160

17. Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext

18. Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://www.nejm.org/doi/full/10.1056/nejme2106315

19. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601

20. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article

21. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/

22. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article

23. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): https://haematologica.org/article/view/haematol.2021.279075

24. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https://www.sciencedirect.com/science/article/pii/S0264410X21005247

25. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478

26. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005

27. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895

28. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315

29. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: https://www.sciencedirect.com/science/article/pii/S0896841121000937

30. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098

31. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://www.sciencedirect.com/science/article/pii/S0953620521002363

32. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: https://www.sciencedirect.com/science/article/pii/S0828282X21006243

33. “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: https://www.sciencedirect.com/science/article/pii/S2666572721000389

34. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://www.sciencedirect.com/science/article/pii/S0196064421003425

35. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1443950621011562

36. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706

37. Prothrombotic immune thrombocytopenia after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0006497121009411

38. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: https://www.sciencedirect.com/science/article/pii/S2589936821000256

39. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046

40. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://www.sciencedirect.com/science/article/pii/S0049384821004369

41. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: https://www.sciencedirect.com/science/article/pii/S0735109721051949

42. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0735675721005714

43. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X

44. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963.

45. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ

46. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: https://www.sciencedirect.com/science/article/pii/S0953620521002314

47. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0213485321000839

48. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/

49. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33606296/

50. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33854395/

51. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/

52. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/

53. Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: https://onlinelibrary.wiley.com/doi/10.1002/ana.26172

54. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/34133027/

55. The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34001390/

56. Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: https://pubmed.ncbi.nlm.nih.gov/34181446/

57. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/

58. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://www.nature.com/articles/s41591-021-01408-4

59. Exacerbation of immune thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34075578/

60. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105244/

61. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: https://www.nejm.org/doi/full/10.1056/NEJMc2106383

62. Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: https://www.nature.com/articles/s41586-021-03744-4

63. Myocarditis with COVID-19 mRNA vaccines: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135

64. Myocarditis and pericarditis after COVID-19 vaccination: https://jamanetwork.com/journals/jama/fullarticle/2782900

65. Myocarditis temporally associated with COVID-19 vaccination: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891.

66. COVID-19 Vaccination Associated with Myocarditis in Adolescents: https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf

67. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https://pubmed.ncbi.nlm.nih.gov/33994339/

68. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: https://www.sciencedirect.com/science/article/pii/S1553838921005789

69. COVID-19 vaccine-induced myocarditis: a case report with review of the literature: https://www.sciencedirect.com/science/article/pii/S1871402121002253

70. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: https://www.sciencedirect.com/science/article/pii/S1936878X2100485X

71. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https://www.sciencedirect.com/science/article/pii/S002234762100617X

72. Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https://www.sciencedirect.com/science/article/pii/S0167527321012286.

73. Acute myocarditis after administration of BNT162b2 vaccine: https://www.sciencedirect.com/science/article/pii/S2214250921001530

74. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: https://www.sciencedirect.com/science/article/pii/S2352906721001573

75. Myocarditis following vaccination with BNT162b2 in a healthy male: https://www.sciencedirect.com/science/article/pii/S0735675721005362

76. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: https://www.sciencedirect.com/science/article/pii/S1930043321005549

77. Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: https://www.sciencedirect.com/science/article/pii/S002234762100665X

78. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: https://www.sciencedirect.com/science/article/pii/S1885585721002218

79. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: https://www.sciencedirect.com/science/article/pii/S2589790X21001931

80. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: https://www.sciencedirect.com/science/article/pii/S2352906721000622

81. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: https://www.sciencedirect.com/science/article/pii/S0022347621007368

82. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: https://www.sciencedirect.com/science/article/pii/S0870255121003243

83. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: https://www.sciencedirect.com/science/article/pii/S0022347621007496

84. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://www.sciencedirect.com/science/article/pii/S1936878X21004861

85. Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: https://www.sciencedirect.com/science/article/pii/S1443950621011331

86. COVID-19 mRNA vaccination and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34268277/

87. COVID-19 vaccine and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34399967/

88. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706.

89. COVID-19 vaccines and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34246566/

90. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp lications-of-the-mrna-based-covid-19-vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines

91. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34340927/

92. Myocarditis with covid-19 mRNA vaccines: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135

93. Association of myocarditis with COVID-19 mRNA vaccine in children: https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co vid-19-vaccine-in-children/

94. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052

95. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C

96. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600

97. Myocarditis following immunization with Covid-19 mRNA: https://www.nejm.org/doi/full/10.1056/NEJMc2109975

98. Patients with acute myocarditis after vaccination withCOVID-19 mRNA: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602

99. Myocarditis associated with vaccination with COVID-19 mRNA: https://pubs.rsna.org/doi/10.1148/radiol.2021211430

100. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: https://pediatrics.aappublications.org/content/148/3/e2021052478

101. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4

102. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis

103. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34402228/

104. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567

105. Myocarditis / pericarditis associated with COVID-19 vaccine: https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html

106. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx

107. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543

108. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/

109. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: https://pubmed.ncbi.nlm.nih.gov/34219532/

110. Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033

111. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236

112. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038

113. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: https://pubmed.ncbi.nlm.nih.gov/34333695/

114. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/

115. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: https://pubmed.ncbi.nlm.nih.gov/34118375/

116. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/

117. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/

118. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/

119. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059

120. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: https://pubmed.ncbi.nlm.nih.gov/34447639/

121. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183

122. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: https://pubmed.ncbi.nlm.nih.gov/34236331/

123. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34435250/

124. COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: https://pubmed.ncbi.nlm.nih.gov/34186348/.

125. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: https://www.sciencedirect.com/science/article/pii/S2666354621000065

126. Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: https://www.sciencedirect.com/science/article/pii/S0303846721004169

127. Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://www.sciencedirect.com/science/article/pii/S0165572821002186

128. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https://www.sciencedirect.com/science/article/pii/S2214250921000998.

129. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: https://www.sciencedirect.com/science/article/pii/S0736467921006442

130. Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://www.sciencedirect.com/science/article/pii/S0035378721005853.

131. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: https://www.sciencedirect.com/science/article/pii/S2049080121005343

132. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: https://www.sciencedirect.com/science/article/pii/S2049080121007536

133. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: https://www.sciencedirect.com/science/article/pii/S1201971221007049

134. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: https://www.sciencedirect.com/science/article/pii/S0899707121003557.

135. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: https://www.sciencedirect.com/science/article/pii/S0165572821001569

136. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: https://www.sciencedirect.com/science/article/pii/S0165572821002137

137. Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: https://www.sciencedirect.com/science/article/pii/S1473309921002735

138. Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: https://www.sciencedirect.com/science/article/pii/S266635462100020X

139. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. https://www.sciencedirect.com/science/article/pii/S2451993621001456.

140. Bell’s palsy after COVID-19 vaccination: case report: https://www.sciencedirect.com/science/article/pii/S217358082100122X.

141. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: https://www.sciencedirect.com/science/article/pii/S2213219821007972

142. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: https://www.sciencedirect.com/science/article/pii/S1930043321002612

143. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https://www.sciencedirect.com/science/article/pii/S0272638621007423

144. Late cutaneous reactions after administration of COVID-19 mRNA vaccines: https://www.sciencedirect.com/science/article/pii/S2213219821007996

145. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: https://www.sciencedirect.com/science/article/pii/S1871402121001880

146. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https://www.sciencedirect.com/science/article/pii/S0190962221024427

147. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381.

148. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. https://www.sciencedirect.com/science/article/pii/S1939455121000119.

149. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. https://www.sciencedirect.com/science/article/pii/S1871402121002046.

150. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X

151. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. https://www.sciencedirect.com/science/article/pii/S0896841121000937.

152. immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. https://www.sciencedirect.com/science/article/pii/S2214250921002018.

153. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: https://www.sciencedirect.com/science/article/pii/S1876034121001878.

154. COVID-19 RNA-based vaccines and the risk of prion disease: https://scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-dis ease-1503.pdf

155. This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: https://www.nejm.org/doi/full/10.1056/NEJMoa2104983.

156. Process-related impurities in the ChAdOx1 nCov-19 vaccine: https://www.researchsquare.com/article/rs-477964/v1

157. COVID-19 mRNA vaccine causing CNS inflammation: a case series: https://link.springer.com/article/10.1007/s00415-021-10780-7

158. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/

159. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: https://pubmed.ncbi.nlm.nih.gov/33320974/

160. Pfizer Vaccine Raises Allergy Concerns: https://pubmed.ncbi.nlm.nih.gov/33384356/

161. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: https://pubmed.ncbi.nlm.nih.gov/33444297/

162. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: https://pubmed.ncbi.nlm.nih.gov/33507892/

163. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: https://pubmed.ncbi.nlm.nih.gov/34414880/

164. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/

165. Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: https://pubmed.ncbi.nlm.nih.gov/34269740/

166. Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34215453/

167. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: https://pubmed.ncbi.nlm.nih.gov/33932618/

168. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/

169. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/33571463/

170. Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/

171. Cutaneous adverse effects of available COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34518015/

172. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: https://pubmed.ncbi.nlm.nih.gov/34347278/

173. COVID-19 vaccines increase the risk of anaphylaxis: https://pubmed.ncbi.nlm.nih.gov/33685103/

174. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/

175. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: https://pubmed.ncbi.nlm.nih.gov/33657648/

176. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33825239/

177. Acute allergic reactions to COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/33683290/

178. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: https://pubmed.ncbi.nlm.nih.gov/33919151/

179. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/

180. Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: https://pubmed.ncbi.nlm.nih.gov/34474708/

181. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447

182. .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34318537/

183. Allergic reactions after COVID-19 vaccination: putting the risk in perspective: https://pubmed.ncbi.nlm.nih.gov/34463751/

184. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.

185. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: https://pubmed.ncbi.nlm.nih.gov/33752263/

186. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/

187. Fatal brain hemorrhage after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/

188. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/

189. Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/

190. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/

191. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: https://pubmed.ncbi.nlm.nih.gov/34254291/

192. Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: https://pubmed.ncbi.nlm.nih.gov/34487581/

193. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: https://pubmed.ncbi.nlm.nih.gov/33987882/

194. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34138513/

195. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/

196. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https://pubmed.ncbi.nlm.nih.gov/34446426/

197. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: https://pubmed.ncbi.nlm.nih.gov/34365148/.

198. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/34452064/.

199. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33917902/

200. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): https://pubmed.ncbi.nlm.nih.gov/34256983/

201. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.

202. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/

203. 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34117206/

204. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: https://pubmed.ncbi.nlm.nih.gov/34033927/

205. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/

206. Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34364831/

207. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: https://pubmed.ncbi.nlm.nih.gov/34447639/

208. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34514306/

209. Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/33946748/

210. Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34453510/

211. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33476455/

212. propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/

213. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34377889/

214. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/

215. COVID-19 vaccination association and facial nerve palsy: A case-control study: https://pubmed.ncbi.nlm.nih.gov/34165512/

216. The association between COVID-19 vaccination and Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/34411533/

217. Bell’s palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33611630/

218. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): https://pubmed.ncbi.nlm.nih.gov/33981305/

219. Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: https://pubmed.ncbi.nlm.nih.gov/34336436/

220. Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34281950/.

221. Transverse myelitis induced by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34458035/

222. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33734623/

223. Acute abducens nerve palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34044114/.

224. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: https://pubmed.ncbi.nlm.nih.gov/34492394/

225. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34369471/

226. Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34014316/

227. Bell’s palsy after COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34330676/

228. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34272622/

229. Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: https://pubmed.ncbi.nlm.nih.gov/34477091/

230. Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33975372/.

231. Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: https://pubmed.ncbi.nlm.nih.gov/34322761/.

232. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: https://pubmed.ncbi.nlm.nih.gov/34139321/.

233. Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: https://pubmed.ncbi.nlm.nih.gov/34032902/.

234. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: https://pubmed.ncbi.nlm.nih.gov/33862041/

235. Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34332438/

236. Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: https://pubmed.ncbi.nlm.nih.gov/34293683/.

237. Autoimmune hepatitis after COVID vaccine: https://pubmed.ncbi.nlm.nih.gov/34225251/

238. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: https://pubmed.ncbi.nlm.nih.gov/34449715/

239. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: https://pubmed.ncbi.nlm.nih.gov/34139631/.

240. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/33864750/

241. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33914590/

242. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34420802/

243. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/

244. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: https://pubmed.ncbi.nlm.nih.gov/34446426/

245. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/

246. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/

247. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/

248. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/

249. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/

250. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: https://pubmed.ncbi.nlm.nih.gov/34261633/.

251. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34256983/

252. Thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332437/.

253. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33845870/.

254. Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: https://pubmed.ncbi.nlm.nih.gov/34236343/

255. Acute myocardial infarction within 24 hours after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34364657/.

256. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34287612/

257. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/

258. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/

259. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/

260. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/

261. A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34137813/

262. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34191218/

263. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/

264. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34153802/

265. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: https://pubmed.ncbi.nlm.nih.gov/34092488/

266. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/

267. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34132839/.

268. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34144250/

269. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/

270. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34011137/.

271. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.

272. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/.

273. Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: https://pubmed.ncbi.nlm.nih.gov/34083026/.

274. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.

275. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: https://pubmed.ncbi.nlm.nih.gov/34235757/.

276. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34473841/.

277. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/

278. Cerebral venous thrombosis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/.

279. Lipschütz ulcers after AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34366434/.

280. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: https://pubmed.ncbi.nlm.nih.gov/34330677/

281. Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: https://pubmed.ncbi.nlm.nih.gov/34181446/

282. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34477089/

283. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34071883/

284. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34033367/

285. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: https://pubmed.ncbi.nlm.nih.gov/34375510/

286. Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34107198/

287. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34355379/.

288. A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: https://pubmed.ncbi.nlm.nih.gov/34452028/

289. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/

290. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.

291. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105247/.

292. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34405870/.

293. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/.

294. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34462013/.

295. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/.

296. Post-vaccinal encephalitis after ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34324214/

297. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: https://pubmed.ncbi.nlm.nih.gov/34507266/

298. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34459725/

299. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https://pubmed.ncbi.nlm.nih.gov/34463066/

300. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: https://pubmed.ncbi.nlm.nih.gov/34043800/.

301. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/

302. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.

303. fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: https://pubmed.ncbi.nlm.nih.gov/34416319/.

304. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/

305. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34291477/

306. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34513435/

307. Hepatitis C virus reactivation after COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34512037/

308. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: https://pubmed.ncbi.nlm.nih.gov/34483273/.

309. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34513446/

310. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34474550/

311. Reactive arthritis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34033732/.

312. Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: https://pubmed.ncbi.nlm.nih.gov/33858208/

313. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: https://pubmed.ncbi.nlm.nih.gov/34015240/

314. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34482558/

315. COVID-19 mRNA vaccine causing CNS inflammation: a case series: https://pubmed.ncbi.nlm.nih.gov/34480607/

316. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: https://pubmed.ncbi.nlm.nih.gov/34462647/

317. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34325334/

318. Tolosa-Hunt syndrome occurring after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34513398/

319. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/

320. Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): https://pubmed.ncbi.nlm.nih.gov/34469919/.

321. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: https://pubmed.ncbi.nlm.nih.gov/34516272/.

322. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: https://pubmed.ncbi.nlm.nih.gov/34512961/

323. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34077949/

324. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34171435/

325. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34447349/

326. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34514078/

327. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34406660/.

328. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34509658/

329. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34196469/.

330. Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: https://pubmed.ncbi.nlm.nih.gov/34350668/

331. Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34436620/

332. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/.

333. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: https://pubmed.ncbi.nlm.nih.gov/34509271/.

334. Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34462996/

335. Immune thrombocytopenia after vaccination during the COVID-19 pandemic: https://pubmed.ncbi.nlm.nih.gov/34435486/

336. COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: https://pubmed.ncbi.nlm.nih.gov/34435142/

337. Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34429981/

338. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: https://pubmed.ncbi.nlm.nih.gov/34427024/

339. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34510014/.

340. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34236711/

341. Vaccine-induced thrombocytopenia with severe headache: https://pubmed.ncbi.nlm.nih.gov/34525282/

342. Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34515024/

343. Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34435250/.

344. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34363637/

345. Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: https://www.sciencedirect.com/science/article/pii/S2214250921002018

346. Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: https://casereports.bmj.com/content/14/5/e242220.abstract.

347. Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34155844/

348. Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.

349. Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.

350. Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.

351. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: https://casereports.bmj.com/content/14/7/e242678.

352. Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic

353. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794

354. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in

355. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/.

356. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/.

357. Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33878469/.

358. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/.

359. Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34090750/.

360. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34312301/.

361. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34333995/

362. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34455073/

363. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34111775/.

364. Cerebral venous thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/

365. Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33983464/

366. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: https://pubmed.ncbi.nlm.nih.gov/34116145/

367. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: https://pubmed.ncbi.nlm.nih.gov/34286453/.

368. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/

369. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/

370. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34226070/

371. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: https://pubmed.ncbi.nlm.nih.gov/33845870/.

372. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/.

373. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.

374. Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/.

375. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: https://pubmed.ncbi.nlm.nih.gov/34313952/

376. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/

377. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/

378. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/

379. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/

380. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/

381. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/

382. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: https://pubmed.ncbi.nlm.nih.gov/33929487/.

383. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/

384. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/

385. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/.

386. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/

387. Autoimmunity roots of thrombotic events after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34508917/

388. Cerebral venous sinus thrombosis after vaccination: the UK experience: https://pubmed.ncbi.nlm.nih.gov/34370974/

389. Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34373991/

390. Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34490632/

391. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33909350/

392. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: https://pubmed.ncbi.nlm.nih.gov/33981305/.

393. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/34272622/

394. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/33877737/

395. Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34254476/

396. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/

397. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/.

398. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/

399. Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/

400. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34273119/

401. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: https://pubmed.ncbi.nlm.nih.gov/34463066/

402. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34276917/

403. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.

404. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34268278/.

405. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33990339/.

406. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.

407. Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: https://pubmed.ncbi.nlm.nih.gov/34314875/.

408. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34384129/

409. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: https://pubmed.ncbi.nlm.nih.gov/34382387/

410. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/.

411. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/

412. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34261296/

413. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: https://pubmed.ncbi.nlm.nih.gov/34250318/.

414. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34059191/

415. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/

416. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/

417. Vaccine-induced thrombocytopenia with severe headache: https://pubmed.ncbi.nlm.nih.gov/34525282/

418. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1

419. COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.

420. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: https://onlinelibrary.wiley.com/doi/10.1111/trf.16672

421. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI

422. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: https://pubmed.ncbi.nlm.nih.gov/34601006/

423. This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475

424. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: https://www.sciencedirect.com/science/article/pii/S1201971221007797

425. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.

426. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: https://www.sciencedirect.com/science/article/pii/S0168827821020936

427. Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: https://www.nature.com/articles/s41421-021-00329-3

428. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/

429. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712

430. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:https://www.science.org/doi/10.1126/sciadv.abl8213

431. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: https://pubmed.ncbi.nlm.nih.gov/34626338/

432. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: https://europepmc.org/article/PPR/PPR304469 435.

433. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34731555/

434. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/

435. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34461442/

436. Spectrum of neurological complications after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34719776/.

437. Cerebral venous sinus thrombosis after vaccination: the UK experience: https://pubmed.ncbi.nlm.nih.gov/34370974/

438. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34373413/

439. Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34598301/

440. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/

441. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: https://pubmed.ncbi.nlm.nih.gov/34650896/

442. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34625447/

443. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: https://pubmed.ncbi.nlm.nih.gov/34696248/

444. Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34548920/

445. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): https://pubmed.ncbi.nlm.nih.gov/34672380/.

446. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: https://pubmed.ncbi.nlm.nih.gov/34556531/.

447. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34535076/.

448. Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: https://pubmed.ncbi.nlm.nih.gov/34379914/.

449. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: https://pubmed.ncbi.nlm.nih.gov/34545400/

450. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34035134/

451. In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34688190/

452. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: https://pubmed.ncbi.nlm.nih.gov/34782400/

453. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34710832/

454. Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: https://pubmed.ncbi.nlm.nih.gov/34695859/

455. Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: https://pubmed.ncbi.nlm.nih.gov/34453762/.

456. Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: https://pubmed.ncbi.nlm.nih.gov/34660652/.

457. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/

458. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: https://pubmed.ncbi.nlm.nih.gov/34694650/

459. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34726934/

460. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: https://pubmed.ncbi.nlm.nih.gov/34835237/

461. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: https://pubmed.ncbi.nlm.nih.gov/34261297/

462. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34724036/.

463. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34839563/

464. Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34783932/.

465. COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: https://pubmed.ncbi.nlm.nih.gov/34624910/

466. Inflammatory myositis after vaccination with ChAdOx1: https://pubmed.ncbi.nlm.nih.gov/34585145/

467. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34580132/.

468. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: https://pubmed.ncbi.nlm.nih.gov/34535492/

469. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: https://pubmed.ncbi.nlm.nih.gov/34527501/

470. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/

471. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: https://pubmed.ncbi.nlm.nih.gov/34756770/

472. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622

473. Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781321/

474. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34062319/

475. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: https://pubmed.ncbi.nlm.nih.gov/34706921/

476. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: https://pubmed.ncbi.nlm.nih.gov/34698582/.

477. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34751013/.

478. Acute transverse myelitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34684047/.

479. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34541935/

480. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34273119/

481. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: https://pubmed.ncbi.nlm.nih.gov/34327553/.

482. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33877737/

483. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34646685/

484. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/.

485. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34609603/

486. Case report: Pityriasis rosea-like rash after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34557507/

487. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34641797/.

488. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: https://pubmed.ncbi.nlm.nih.gov/34812326/.

489. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): https://pubmed.ncbi.nlm.nih.gov/34006408/

490. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/

491. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: https://pubmed.ncbi.nlm.nih.gov/34664303/.

492. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34649281/.

493. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34420249/

494. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34610990/.

495. Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34590397/

496. Sudden sensorineural hearing loss after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34670143/.

497. Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: https://pubmed.ncbi.nlm.nih.gov/34819146/.

498. Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34581453/

499. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/

500. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34631069/

501. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: https://pubmed.ncbi.nlm.nih.gov/34479129/

502. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34331506/

503. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): https://pubmed.ncbi.nlm.nih.gov/34546608/

504. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34546343/

505. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34849183/

506. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34853744/.

507. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): https://pubmed.ncbi.nlm.nih.gov/34751429/.

508. Ocular adverse events following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34559576/

509. Depression after ChAdOx1-S / nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34608345/.

510. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34384129/.

511. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: https://pubmed.ncbi.nlm.nih.gov/34755433/

512. Major artery thrombosis and vaccination against ChAdOx1 nCov-19: https://pubmed.ncbi.nlm.nih.gov/34839830/

513. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: https://pubmed.ncbi.nlm.nih.gov/34667486/

514. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: https://pubmed.ncbi.nlm.nih.gov/34726187/.

515. Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781027/

516. Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: https://pubmed.ncbi.nlm.nih.gov/34595694/

517. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: https://pubmed.ncbi.nlm.nih.gov/34661934/

518. Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34788138

519. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34753210/.

520. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34653943/.

521. Relapse of immune thrombocytopenia after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34591991/

522. Thrombosis in pre- and post-vaccination phase of COVID-19; https://pubmed.ncbi.nlm.nih.gov/34650382/

523. A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: https://pubmed.ncbi.nlm.nih.gov/34769454/

524. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: https://pubmed.ncbi.nlm.nih.gov/34786893/

525. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: https://pubmed.ncbi.nlm.nih.gov/34833382/

526. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): https://pubmed.ncbi.nlm.nih.gov/34670287/

527. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34790811/

528. Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: https://pubmed.ncbi.nlm.nih.gov/34023956/.

529. Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: https://pubmed.ncbi.nlm.nih.gov/34629931/

530. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/

531. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34842783/

532. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34630307/

533. Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33983464/

534. Autoimmune roots of thrombotic events after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34508917/.

535. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.

536. Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33962903/.

537. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34796065/.

538. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: https://pubmed.ncbi.nlm.nih.gov/34579248/

539. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: https://pubmed.ncbi.nlm.nih.gov/34843991/

540. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): https://pubmed.ncbi.nlm.nih.gov/34595867/

541. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): https://pubmed.ncbi.nlm.nih.gov/34820240/

542. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: https://pubmed.ncbi.nlm.nih.gov/33851389/

543. Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: https://pubmed.ncbi.nlm.nih.gov/33980419/

544. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34264151/

545. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/

546. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: https://pubmed.ncbi.nlm.nih.gov/34755555/

547. Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/

548. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34264514/.

549. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34840204/

550. Neurological side effects of SARS-CoV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34750810/

551. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: https://pubmed.ncbi.nlm.nih.gov/34639132/

552. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: https://pubmed.ncbi.nlm.nih.gov/34804412/

553. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: https://pubmed.ncbi.nlm.nih.gov/34571653/.

554. Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: https://pubmed.ncbi.nlm.nih.gov/34835275/.

555. Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: https://pubmed.ncbi.nlm.nih.gov/34659839/.

556. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34668274/.

557. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34549821/

558. Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): https://pubmed.ncbi.nlm.nih.gov/34528522/

559. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/

560. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644 5179.

561. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408

562. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106

563. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https://pubmed.ncbi.nlm.nih.gov/34402230/

564. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/

565. Myocarditis Following mRNA COVID-19 Vaccine: https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.

566. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: https://pubmed.ncbi.nlm.nih.gov/34614328/.

567. Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext

568. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/

569. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: https://pubmed.ncbi.nlm.nih.gov/34246586/

570. Hypersensitivity Myocarditis and COVID-19 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34856634/.

571. Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext.

572. Acute myocardial infarction and myocarditis after COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/

573. Myocarditis after Covid-19 vaccination in a large healthcare organization: https://www.nejm.org/doi/10.1056/NEJMoa2110737

574. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052

575. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

576. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. https://pubmed.ncbi.nlm.nih.gov/34756746/

577. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/

578. Myocarditis after COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34546329/.

579. Patients with acute myocarditis after COVID-19 mRNA vaccination:. https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602.

580. Myocarditis after COVID-19 vaccination: a case series: https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub.

581. Myocarditis associated with COVID-19 vaccination in adolescents: https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357

582. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34704459/

583. Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6 421640.

584. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/

585. Myocarditis after COVID-19 vaccination: https://www.sciencedirect.com/science/article/pii/S2352906721001603

586. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/.

587. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X.

588. Myocarditis associated with COVID-19 mRNA vaccination: https://pubs.rsna.org/doi/10.1148/radiol.2021211430

589. Acute myocarditis after COVID-19 vaccination: a case report: https://www.sciencedirect.com/science/article/pii/S0248866321007098

590. Acute myopericarditis after COVID-19 vaccination in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34589238/.

591. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: https://academic.oup.com/jpids/article/10/10/962/6329543.

592. Acute myocarditis associated with anti-COVID-19 vaccination: https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.

593. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. https://pubmed.ncbi.nlm.nih.gov/34428917/.

594. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. https://pubmed.ncbi.nlm.nih.gov/34088762/.

595. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/64 42104.

596. COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: https://www.mdpi.com/2036-7503/13/3/61.

597. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34402228/

598. Myocarditis temporally associated with COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34133885/

599. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: https://pubmed.ncbi.nlm.nih.gov/34219532/

600. Acute myocarditis associated with COVID-19 vaccination: report of a case: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/

601. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: https://pubmed.ncbi.nlm.nih.gov/34840235/.

602. Myocarditis in the setting of a recent COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34712497/.

603. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.

604. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34568726/

605. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179

606. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408.

607. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: https://www.mdpi.com/2075-4426/11/11/1106

608. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: https://pubmed.ncbi.nlm.nih.gov/34402230/

609. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/

610. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34615534/

611. Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/

612. Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.

613. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: https://pubmed.ncbi.nlm.nih.gov/34632750/

614. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: https://haematologica.org/article/view/haematol.2021.279075

615. COVID-19 vaccine-induced thrombosis: https://pubmed.ncbi.nlm.nih.gov/34802488/.

616. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: https://pubmed.ncbi.nlm.nih.gov/34887867/.

617. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34863404/.

618. Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: https://www.sciencedirect.com/science/article/pii/S235255682100093X

619. Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34876440/

620. Deep venous thrombosis more than two weeks after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33928773/

621. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34880826/

622. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34587242/

623. Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: https://pubmed.ncbi.nlm.nih.gov/34868465/

624. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): https://pubmed.ncbi.nlm.nih.gov/34097311/

625. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: https://pubmed.ncbi.nlm.nih.gov/34820232/.

626. Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258

627. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: https://pubmed.ncbi.nlm.nih.gov/34579636/

628. Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: https://pubmed.ncbi.nlm.nih.gov/34614491/

629. Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: https://pubmed.ncbi.nlm.nih.gov/34790684/

630. Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33624509/.

631. Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): https://pubmed.ncbi.nlm.nih.gov/34612003/

632. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: https://pubmed.ncbi.nlm.nih.gov/34096082/

633. Myocarditis associated with COVID-19 vaccination in three adolescent boys: https://pubmed.ncbi.nlm.nih.gov/34851078/.

634. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34496880/

635. Perimyocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34866957/

636. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: https://pubmed.ncbi.nlm.nih.gov/34849657/.

637. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: https://pubmed.ncbi.nlm.nih.gov/34664804/

638. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: https://pubmed.ncbi.nlm.nih.gov/34605853/

639. Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: https://pubmed.ncbi.nlm.nih.gov/34166671/

640. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34744118/

641. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: https://pubmed.ncbi.nlm.nih.gov/34334935/.

642. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34746968/

643. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: https://pubmed.ncbi.nlm.nih.gov/34333695/.

644. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34180390/

645. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: https://pubmed.ncbi.nlm.nih.gov/34185045/

646. Myocarditis after BNT162b2 vaccination in a healthy male: https://pubmed.ncbi.nlm.nih.gov/34229940/

647. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/

648. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34308326/.

649. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: https://pubmed.ncbi.nlm.nih.gov/34866106/

650. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/

651. Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34848416/

652. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: https://pubmed.ncbi.nlm.nih.gov/34636504/

653. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34367386/

654. Acute myocarditis in a young adult two days after vaccination with Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709227/

655. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/

656. Acute myocarditis after 2019 coronavirus disease vaccination: https://pubmed.ncbi.nlm.nih.gov/34734821/

657. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34246585/

658. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34228985/

659. Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34852213/

660. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: https://pubmed.ncbi.nlm.nih.gov/34866122/

661. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: https://pubmed.ncbi.nlm.nih.gov/34601566/

662. Myocarditis following COVID-19 vaccination: MRI study: https://pubmed.ncbi.nlm.nih.gov/34739045/.

663. Acute myocarditis after COVID-19 vaccination: case report: https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e

664. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/

665. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: https://pubmed.ncbi.nlm.nih.gov/34865500/

666. Myocarditis following vaccination with Covid-19 in a large healthcare organization: https://pubmed.ncbi.nlm.nih.gov/34614329/

667. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: https://pubmed.ncbi.nlm.nih.gov/34560365/

668. COVID-19, Guillain-Barré and vaccineA dangerous mix: https://pubmed.ncbi.nlm.nih.gov/34108736/.

669. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/34796417/.

670. Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: https://link.springer.com/article/10.1007%2Fs10072-021-05523-5.

671. COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: https://onlinelibrary.wiley.com/doi/10.1002/ana.26258.

672. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: https://jamanetwork.com/journals/jama/fullarticle/2785009

673. A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34567447/

674. Guillain-Barré syndrome associated with COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34648420/.

675. Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708

676. Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.

677. Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34114256/.

678. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34767184/.

679. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: https://pubmed.ncbi.nlm.nih.gov/34644738/.

680. Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: https://pubmed.ncbi.nlm.nih.gov/34649856/

681. A rare case of Guillain-Barré syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34671572/

682. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33758714/

683. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: https://pubmed.ncbi.nlm.nih.gov/34484780/

684. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; https://pubmed.ncbi.nlm.nih.gov/34779385/.

685. Miller Fisher syndrome after Pfizer COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34817727/.

686. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: https://pubmed.ncbi.nlm.nih.gov/34789193/.

687. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261746/

688. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: https://pubmed.ncbi.nlm.nih.gov/34217513/.

689. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): https://pubmed.ncbi.nlm.nih.gov/34871447/

690. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/

691. A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: https://pubmed.ncbi.nlm.nih.gov/34370408/.

692. A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34703690/.

693. Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: https://pubmed.ncbi.nlm.nih.gov/34810163/

694. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218.

695. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34482455/.

696. Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34114269/.

697. Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: https://pubmed.ncbi.nlm.nih.gov/34722067/

698. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: https://pubmed.ncbi.nlm.nih.gov/33968610/

699. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/

700. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: https://pubmed.ncbi.nlm.nih.gov/34808658/

701. Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext.

702. Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: https://pubmed.ncbi.nlm.nih.gov/34522557/

703. Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34763263/.

704. Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/

705. Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34697502/

706. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/33858693/

707. Acute transverse myelitis following inactivated COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34370410/

708. Acute transverse myelitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34579245/.

709. A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34182207/

710. Post COVID-19 transverse myelitis; a case report with review of the literature: https://pubmed.ncbi.nlm.nih.gov/34457267/.

711. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/

712. Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34660149/

713. Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/

714. A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: https://pubmed.ncbi.nlm.nih.gov/34635376/

715. Acute pericarditis and cardiac tamponade after vaccination with Covid-19: https://pubmed.ncbi.nlm.nih.gov/34749492/

716. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34849667/

717. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34319393/

718. Acute myopericarditis after COVID-19 vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34589238/

719. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34149145/

720. Case report: symptomatic pericarditis post COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34693198/.

721. An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: https://pubmed.ncbi.nlm.nih.gov/34797392/

722. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): https://pubmed.ncbi.nlm.nih.gov/34862234/

723. Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: https://pubmed.ncbi.nlm.nih.gov/34396358/.

724. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34848426/.

725. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/33946748/

726. Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34591186/

727. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34352309/

728. Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: https://pubmed.ncbi.nlm.nih.gov/34804803/.

729. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: https://pubmed.ncbi.nlm.nih.gov/34077572/

730. Retinal hemorrhage after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34884407/.

731. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34859017/

732. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34783899/

733. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34549178/.

734. Brain death in a vaccinated patient with COVID-19 infection: https://pubmed.ncbi.nlm.nih.gov/34656887/

735. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34236717/.

736. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34729467/.

737. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/33932458/

738. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: https://pubmed.ncbi.nlm.nih.gov/34092400/742.

739. Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34754937/

740. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/

741. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34846583/

742. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/

743. Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: https://pubmed.ncbi.nlm.nih.gov/34411532/

744. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1

745. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: https://pubmed.ncbi.nlm.nih.gov/33851711/

746. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: https://pubmed.ncbi.nlm.nih.gov/34675550/.

747. Anaphylaxis after Modern COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34734159/.

748. Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34698847/

749. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: https://pubmed.ncbi.nlm.nih.gov/34020815/

750. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: https://pubmed.ncbi.nlm.nih.gov/33641264/

751. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: https://pubmed.ncbi.nlm.nih.gov/33641268/

752. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: https://pubmed.ncbi.nlm.nih.gov/33834172/

753. Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34579211/

754. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: https://pubmed.ncbi.nlm.nih.gov/34343674/

755. Acute myocardial infarction and myocarditis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34586408/

756. Takotsubo syndrome after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34539938/.

757. Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: https://pubmed.ncbi.nlm.nih.gov/34731486/.

758. Premature myocardial infarction or side effect of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33824804/

759. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: https://pubmed.ncbi.nlm.nih.gov/34807248/

760. Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34148772/

761. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: https://pubmed.ncbi.nlm.nih.gov/34702550/

762. Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®): https://pubmed.ncbi.nlm.nih.gov/33895650/

763. Deaths associated with recently launched SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34425384/

764. A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: https://pubmed.ncbi.nlm.nih.gov/34703815/

765. COVID-19 vaccine-induced urticarial vasculitis: https://pubmed.ncbi.nlm.nih.gov/34369046/.

766. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34280507/.

767. New-onset leukocytoclastic vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34241833/

768. Cutaneous small vessel vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34529877/.

769. Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928638/

770. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34836739/

771. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; https://pubmed.ncbi.nlm.nih.gov/34495381/.

772. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34327795

773. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34660867/.

774. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34659268/

775. Reactivation of IgA vasculitis after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34848431/

776. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34310759/.

777. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: https://pubmed.ncbi.nlm.nih.gov/34720009/

778. A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34518812/

779. Cutaneous vasculitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34611627/.

780. Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34705320/.

781. IgA vasculitis following COVID-19 vaccination in an adult: https://pubmed.ncbi.nlm.nih.gov/34779011/

782. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34451967/

783. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: https://pubmed.ncbi.nlm.nih.gov/33928459/

784. Reactivation of IgA vasculitis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34250509/

785. Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34292611/.

786. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: https://pubmed.ncbi.nlm.nih.gov/34530771/.

787. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/.

788. Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34599716/.

789. Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: https://pubmed.ncbi.nlm.nih.gov/34115904/.

790. Henoch-Schönlein purpura occurring after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34247902/.

791. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34696186/.

792. Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34237323/.

793. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34851795/.

794. A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34849386/

795. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34310763/

796. Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: https://pubmed.ncbi.nlm.nih.gov/34251683/.

797. Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34557622/.

798. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34510694/

799. Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: https://pubmed.ncbi.nlm.nih.gov/34713472/803

800. Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34819272/

801. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34337124/

802. Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: https://pubmed.ncbi.nlm.nih.gov/34535924/

803. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/

804. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: https://pubmed.ncbi.nlm.nih.gov/33591026/

805. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: https://pubmed.ncbi.nlm.nih.gov/33625300/

806. Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: https://pubmed.ncbi.nlm.nih.gov/33774684/

807. Lymphadenopathy after COVID-19 vaccination: review of imaging findings: https://pubmed.ncbi.nlm.nih.gov/33985872/

808. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/

809. Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: https://pubmed.ncbi.nlm.nih.gov/34115709/.

810. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: https://pubmed.ncbi.nlm.nih.gov/34257025/.

811. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: https://pubmed.ncbi.nlm.nih.gov/34836672/.

812. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: https://pubmed.ncbi.nlm.nih.gov/34280870/

813. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: https://pubmed.ncbi.nlm.nih.gov/34432391/

814. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: https://pubmed.ncbi.nlm.nih.gov/34731748/

815. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: https://pubmed.ncbi.nlm.nih.gov/34906409/

816. Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/

817. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/

818. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/

819. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/

820. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/

821. A case of cervical lymphadenopathy following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34141500/

822. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/

823. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/

824. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/

825. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https://pubmed.ncbi.nlm.nih.gov/34298342/

826. A systematic review of cases of CNS demyelination following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34839149/

827. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/

828. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/

829. Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.

830. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34292295/.

831. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.

832. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https://pubmed.ncbi.nlm.nih.gov/34526175/

833. Lymphadenopathy associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33786231/

834. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625301/.

835. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332438/.

836. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.

837. Massive cervical lymphadenopathy following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34601889/

838. ANCA glomerulonephritis following Modern COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34081948/

839. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.

840. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/

841. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/

842. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.

843. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/

844. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.

845. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34187985/.

846. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/

847. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/

848. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/

849. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/

850. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/

851. A case of cervical lymphadenopathy following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34141500/

852. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/

853. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/

854. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/

855. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: https://pubmed.ncbi.nlm.nih.gov/34298342/

856. A systematic review of cases of CNS demyelination following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34839149/

857. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/

858. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/

859. Adenopathy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625299/.

860. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34292295/.

861. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.

862. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: https://pubmed.ncbi.nlm.nih.gov/34526175/

863. Lymphadenopathy associated with the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33786231/

864. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33625301/.

865. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34332438/.

866. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.

867. Massive cervical lymphadenopathy following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34601889/

868. ANCA glomerulonephritis following Modern COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34081948/

869. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34507942/.

870. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/

871. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/

872. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.

873. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/

874. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.

875. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34187985/.

876. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. https://www.ncbi.nlm.nih.gov/pubmed/34416319

877. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/pubmed/34092429

878. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885

879. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408

880. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. https://www.ncbi.nlm.nih.gov/pubmed/34756746

881. Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. https://www.ncbi.nlm.nih.gov/pubmed/34432976

882. Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. https://www.ncbi.nlm.nih.gov/pubmed/34754400

883. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. https://www.ncbi.nlm.nih.gov/pubmed/34281357

884. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284

885. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. https://www.ncbi.nlm.nih.gov/pubmed/34366403

886. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344

887. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. https://www.ncbi.nlm.nih.gov/pubmed/34617315

888. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. https://www.ncbi.nlm.nih.gov/pubmed/34333695

889. Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. https://www.ncbi.nlm.nih.gov/pubmed/34833382

890. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. https://www.ncbi.nlm.nih.gov/pubmed/34704459

891. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. https://www.ncbi.nlm.nih.gov/pubmed/34664804

892. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. https://www.ncbi.nlm.nih.gov/pubmed/34860360

893. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657

894. Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/34933012

895. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. https://www.ncbi.nlm.nih.gov/pubmed/34547487

896. Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. https://www.ncbi.nlm.nih.gov/pubmed/34339728

897. Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/pubmed/34356586

898. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. https://www.ncbi.nlm.nih.gov/pubmed/34219532

899. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. https://www.ncbi.nlm.nih.gov/pubmed/34246585

900. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161

901. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. https://www.ncbi.nlm.nih.gov/pubmed/34844930

902. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. https://www.ncbi.nlm.nih.gov/pubmed/34487236

903. El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. https://www.ncbi.nlm.nih.gov/pubmed/34551225

904. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/34709227

905. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. https://www.ncbi.nlm.nih.gov/pubmed/34921468

906. Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. https://www.ncbi.nlm.nih.gov/pubmed/34824230

907. Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. https://www.ncbi.nlm.nih.gov/pubmed/34170372

908. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667

909. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. https://www.ncbi.nlm.nih.gov/pubmed/34646267

910. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. https://www.ncbi.nlm.nih.gov/pubmed/34127481

911. Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. https://www.ncbi.nlm.nih.gov/pubmed/34538306

912. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/34237049

913. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694

914. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088

915. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. https://www.ncbi.nlm.nih.gov/pubmed/34916217

916. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517

917. Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. https://www.ncbi.nlm.nih.gov/pubmed/34668687

918. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. https://www.ncbi.nlm.nih.gov/pubmed/34348657

919. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. https://www.ncbi.nlm.nih.gov/pubmed/34351881

920. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395

921. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/pubmed/34446426

922. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/pubmed/34808708

923. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. https://www.ncbi.nlm.nih.gov/pubmed/34347278

924. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/3454412

925. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755

926. Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. https://www.ncbi.nlm.nih.gov/pubmed/34931681

927. Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. https://www.ncbi.nlm.nih.gov/pubmed/34342500

928. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376

929. Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. https://www.ncbi.nlm.nih.gov/pubmed/34834983

930. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. https://www.ncbi.nlm.nih.gov/pubmed/34389692

931. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. https://www.ncbi.nlm.nih.gov/pubmed/34270752

932. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. https://www.ncbi.nlm.nih.gov/pubmed/34744118

933. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/34568540

934. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. https://www.ncbi.nlm.nih.gov/pubmed/34447639

935. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046

936. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. https://www.ncbi.nlm.nih.gov/pubmed/34402228

937. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358

938. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. https://www.ncbi.nlm.nih.gov/pubmed/34477808

939. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. https://www.ncbi.nlm.nih.gov/pubmed/33898162

940. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. https://www.ncbi.nlm.nih.gov/pubmed/33643776

941. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. https://www.ncbi.nlm.nih.gov/pubmed/34952008

942. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. https://www.ncbi.nlm.nih.gov/pubmed/34642628

943. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. https://www.ncbi.nlm.nih.gov/pubmed/34540594

944. Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. https://www.ncbi.nlm.nih.gov/pubmed/34378087

945. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. https://www.ncbi.nlm.nih.gov/pubmed/34127854

946. Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/pubmed/34393110

947. Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. https://www.ncbi.nlm.nih.gov/pubmed/34463770

948. Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. https://www.ncbi.nlm.nih.gov/pubmed/33606296

949. Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. https://www.ncbi.nlm.nih.gov/pubmed/34535317

950. Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. https://www.ncbi.nlm.nih.gov/pubmed/33888900

951. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/34834458

952. Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411

953. Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057. https://www.ncbi.nlm.nih.gov/pubmed/34332972

954. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001. https://www.ncbi.nlm.nih.gov/pubmed/34375696

955. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. doi:10.1093/cid/ciab954. https://www.ncbi.nlm.nih.gov/pubmed/34791081

956. Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131. doi:10.1155/2021/6901131. https://www.ncbi.nlm.nih.gov/pubmed/34676123

957. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295. doi:10.1002/pbc.29295. https://www.ncbi.nlm.nih.gov/pubmed/34398511

958. Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study. Public Health, 190, 4-6. doi:10.1016/j.puhe.2020.11.005. https://www.ncbi.nlm.nih.gov/pubmed/33316478

959. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/34133825

960. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. https://www.ncbi.nlm.nih.gov/pubmed/34614328

961. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. https://www.ncbi.nlm.nih.gov/pubmed/34166671

962. Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun, 12(1), 6379. doi:10.1038/s41467-021-26672-3. https://www.ncbi.nlm.nih.gov/pubmed/34737312

963. Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-20. https://www.ncbi.nlm.nih.gov/pubmed/33526560

964. Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-06949-0. https://www.ncbi.nlm.nih.gov/pubmed/34930152

965. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045

966. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. https://www.ncbi.nlm.nih.gov/pubmed/34840235

967. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006. https://www.ncbi.nlm.nih.gov/pubmed/34876937

968. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765. doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859

969. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/34889875

970. Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-4. https://www.ncbi.nlm.nih.gov/pubmed/34320609

971. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232. https://www.ncbi.nlm.nih.gov/pubmed/34402230

972. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390

973. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4. https://www.ncbi.nlm.nih.gov/pubmed/34496880

974. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-0. https://www.ncbi.nlm.nih.gov/pubmed/34907393

975. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386

976. Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093/cid/ciab926. https://www.ncbi.nlm.nih.gov/pubmed/34734240

977. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9. https://www.ncbi.nlm.nih.gov/pubmed/34738774

978. Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42. doi:10.1002/ajh.26385. https://www.ncbi.nlm.nih.gov/pubmed/34695229

979. Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34. doi:10.1016/j.ejca.2021.06.002. https://www.ncbi.nlm.nih.gov/pubmed/34233234

980. Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252. doi:10.1148/ryct.210252. https://www.ncbi.nlm.nih.gov/pubmed/34934954

981. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083. https://www.ncbi.nlm.nih.gov/pubmed/34228985

982. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9. https://www.ncbi.nlm.nih.gov/pubmed/34591186

983. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5. https://www.ncbi.nlm.nih.gov/pubmed/34241676

984. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390/jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172

985. Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389/fimmu.2021.714170. https://www.ncbi.nlm.nih.gov/pubmed/34707602

986. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. https://www.ncbi.nlm.nih.gov/pubmed/33956784

987. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383. doi:10.7759/cureus.16383. https://www.ncbi.nlm.nih.gov/pubmed/34408937

988. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230. https://www.ncbi.nlm.nih.gov/pubmed/34739045

989. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/34605853

990. Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797

991. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-1. https://www.ncbi.nlm.nih.gov/pubmed/34764489

992. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/34077949

993. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. doi:10.1016/j.healun.2021.11.001. https://www.ncbi.nlm.nih.gov/pubmed/34911654

994. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430. https://www.ncbi.nlm.nih.gov/pubmed/34282971

995. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869

996. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319. https://www.ncbi.nlm.nih.gov/pubmed/34514306

997. Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935. https://www.ncbi.nlm.nih.gov/pubmed/34955479

998. Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. https://www.ncbi.nlm.nih.gov/pubmed/33444297

999. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329. doi:10.1056/NEJMoa2107058. https://www.ncbi.nlm.nih.gov/pubmed/34192428

1000. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634. https://www.ncbi.nlm.nih.gov/pubmed/34866957

1001. Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. Circulation. doi:10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/34865500

1002. Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926. https://www.ncbi.nlm.nih.gov/pubmed/34311983

1003. Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/pubmed/34904134

1004. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759/cureus.15576. https://www.ncbi.nlm.nih.gov/pubmed/34277198

1005. Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi:10.1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/34731877

1006. Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/34533570

1007. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940

1008. Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health, 9, 695807. doi:10.3389/fpubh.2021.695807. https://www.ncbi.nlm.nih.gov/pubmed/34336774

1009. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054. https://www.ncbi.nlm.nih.gov/pubmed/34006408

1010. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737. https://www.ncbi.nlm.nih.gov/pubmed/34614329

1011. Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-320338. https://www.ncbi.nlm.nih.gov/pubmed/33262177

I recently resigned from my position as full tenured professor at the University of Toronto. I am now professor emeritus, and before I turned sixty. Emeritus is generally a designation reserved for superannuated faculty, albeit those who had served their term with some distinction. I had envisioned teaching and researching at the U of T, full time, until they had to haul my skeleton out of my office. I loved my job. And my students, undergraduates and graduates alike, were positively predisposed toward me. But that career path was not meant to be. There were many reasons, including the fact that I can now teach many more people and with less interference online. But here’s a few more:

First, my qualified and supremely trained heterosexual white male graduate students (and I’ve had many others, by the way) face a negligible chance of being offered university research positions, despite stellar scientific dossiers. This is partly because of Diversity, Inclusivity and Equity mandates (my preferred acronym: DIE). These have been imposed universally in academia, despite the fact that university hiring committees had already done everything reasonable for all the years of my career, and then some, to ensure that no qualified “minority” candidates were ever overlooked. My students are also partly unacceptable precisely because they are my students. I am academic persona non grata, because of my unacceptable philosophical positions. And this isn’t just some inconvenience. These facts rendered my job morally untenable. How can I accept prospective researchers and train them in good conscience knowing their employment prospects to be minimal?

Second reason: This is one of many issues of appalling ideology currently demolishing the universities and, downstream, the general culture. Not least because there simply is not enough qualified BIPOC people in the pipeline to meet diversity targets quickly enough (BIPOC: black, indigenous and people of colour, for those of you not in the knowing woke). This has been common knowledge among any remotely truthful academic who has served on a hiring committee for the last three decades. This means we’re out to produce a generation of researchers utterly unqualified for the job. And we’ve seen what that means already in the horrible grievance studies “disciplines.” That, combined with the death of objective testing, has compromised the universities so badly that it can hardly be overstated. And what happens in the universities eventually colours everything. As we have discovered.

All my craven colleagues must craft DIE statements to obtain a research grant. They all lie (excepting the minority of true believers) and they teach their students to do the same. And they do it constantly, with various rationalizations and justifications, further corrupting what is already a stunningly corrupt enterprise. Some of my colleagues even allow themselves to undergo so-called anti-bias training, conducted by supremely unqualified Human Resources personnel, lecturing inanely and blithely and in an accusatory manner about theoretically all-pervasive racist/sexist/heterosexist attitudes. Such training is now often a precondition to occupy a faculty position on a hiring committee.

Need I point out that implicit attitudes cannot — by the definitions generated by those who have made them a central point of our culture — be transformed by short-term explicit training? Assuming that those biases exist in the manner claimed, and that is a very weak claim, and I’m speaking scientifically here. The Implicit Association test — the much-vaunted IAT, which purports to objectively diagnose implicit bias (that’s automatic racism and the like) is by no means powerful enough — valid and reliable enough — to do what it purports to do. Two of the original designers of that test, Anthony Greenwald and Brian Nosek, have said as much, publicly. The third, Professor Mahzarin Banaji of Harvard, remains recalcitrant. Much of this can be attributed to her overtly leftist political agenda, as well as to her embeddedness within a sub-discipline of psychology, social psychology, so corrupt that it denied the existence of left-wing authoritarianism for six decades after World War II. The same social psychologists, broadly speaking, also casually regard conservatism (in the guise of “system justification”) as a form of psychopathology.

Banaji’s continued countenancing of the misuse of her research instrument, combined with the status of her position at Harvard, is a prime reason we still suffer under the DIE yoke, with its baleful effect on what was once the closest we had ever come to truly meritorious selection. There are good reasons to suppose that DIE-motivated eradication of objective testing, such as the GRE for graduate school admission, will have deleterious effects on the ability of students so selected to master such topics as the statistics all social sciences (and medicine, for that matter) rely upon completely for their validity.

Furthermore, the accrediting boards for graduate clinical psychology training programs in Canada are now planning to refuse to accredit university clinical programs unless they have a “social justice” orientation. That, combined with some recent legislative changes in Canada, claiming to outlaw so-called “conversion therapy” (but really making it exceedingly risky for clinicians to do anything ever but agree always and about everything with their clients) have likely doomed the practice of clinical psychology, which always depended entirely on trust and privacy. Similar moves are afoot in other professional disciplines, such as medicine and law. And if you don’t think that psychologists, lawyers and other professionals are anything but terrified of their now woke governing professional colleges, much to everyone’s extreme detriment, you simply don’t understand how far this has all gone.

Just exactly what am I supposed to do when I meet a graduate student or young professor, hired on DIE grounds? Manifest instant skepticism regarding their professional ability? What a slap in the face to a truly meritorious young outsider. And perhaps that’s the point. The DIE ideology is not friend to peace and tolerance. It is absolutely and completely the enemy of competence and justice.

And for those of you who think that I am overstating the case, or that this is something limited in some trivial sense to the universities, consider some other examples: This report from Hollywood, cliched hotbed of “liberal” sentiment, for example, indicates just how far this has gone. In 2020, the Academy of Motion Picture Arts and Sciences (the Oscar people) embarked on a five-year plan (does that ring any historical bells?) “to diversify our organization and expand our definition of the best,” They did so in an attempt which included developing “new representation and inclusion standards for Oscars,” to, hypothetically, “better reflect the diversity of the movie-going audience.” What fruit has this initiative, offspring of the DIE ideology, borne? According to a recent article, penned by Peter Kiefer and Peter Savodnik, but posted on former NY Times’ journalist Bari Weiss’s Common Sense website (and Weiss left the Times, because of the intrusion of radical left ideology into that newspaper, just as Tara Henley did recently, vis a vis the CBC): “We spoke to more than 25 writers, directors, and producers — all of whom identify as liberal, and all of whom described a pervasive fear of running afoul of the new dogma. … How to survive the revolution? By becoming its most ardent supporter. … Suddenly, every conversation with every agent or head of content started with: Is anyone BIPOC attached to this?”

And this is everywhere — and if you don’t see it, your head is either in the sand or shoved somewhere far more unmentionable. CBS, for example, has literally mandated that every writers’ room be at least 40 per cent BIPOC in 2021 (50 per cent in 2022).

We are now at the point where race, ethnicity, “gender,” or sexual preference is first, accepted as the fundamental characteristic defining each person (just as the radical leftists were hoping) and second, is now treated as the most important qualification for study, research and employment.

Need I point out that this is insane ? Even the benighted New York Times has its doubts. A headline from August 11, 2021: Are Workplace Diversity Programs Doing More Harm than Good? In a word, yes. How can accusing your employees of racism etc. sufficient to require re-training (particularly in relationship to those who are working in good faith to overcome whatever bias they might still, in these modern, liberal times, manifest) be anything other than insulting, annoying, invasive, high-handed, moralizing, inappropriate, ill-considered, counterproductive, and otherwise unjustifiable?

And if you think DIE is bad, wait until you get a load of Environmental, Social and Governance (ESG) scores . Purporting to assess corporate moral responsibility, these scores, which can dramatically affect an enterprise’s financial viability, are nothing less than the equivalent of China’s damnable social credit system, applied to the entrepreneurial and financial world. CEOs: what in the world is wrong with you? Can’t you see that the ideologues who push such appalling nonsense are driven by an agenda that is not only absolutely antithetical to your free-market enterprise, as such, but precisely targeted at the freedoms that made your success possible? Can’t you see that by going along, sheep-like (just as the professors are doing; just as the artists and writers are doing) that you are generating a veritable fifth column within your businesses? Are you really so blind, cowed and cowardly? With all your so-called privilege?

And it’s not just the universities. And the professional colleges. And Hollywood. And the corporate world. Diversity, Inclusivity and Equity — that radical leftist Trinity — is destroying us. Wondering about the divisiveness that is currently besetting us? Look no farther than DIE. Wondering — more specifically — about the attractiveness of Trump? Look no farther than DIE. When does the left go too far? When they worship at the altar of DIE, and insist that the rest of us, who mostly want to be left alone, do so as well. Enough already. Enough. Enough.

Finally, do you know that Vladimir Putin himself is capitalizing on this woke madness? Anna Mahjar-Barducci at MEMRI.org covered his recent speech. I quote from the article’s translation: “The advocates of so-called ‘social progress’ believe they are introducing humanity to some kind of a new and better consciousness. Godspeed, hoist the flags, as we say, go right ahead. The only thing that I want to say now is that their prescriptions are not new at all. It may come as a surprise to some people, but Russia has been there already. After the 1917 revolution, the Bolsheviks, relying on the dogmas of Marx and Engels, also said that they would change existing ways and customs, and not just political and economic ones, but the very notion of human morality and the foundations of a healthy society. The destruction of age-old values, religion, and relations between people, up to and including the total rejection of family (we had that, too), encouragement to inform on loved ones — all this was proclaimed progress and, by the way, was widely supported around the world back then and was quite fashionable, same as today. By the way, the Bolsheviks were absolutely intolerant of opinions other than theirs.

“This, I believe, should call to mind some of what we are witnessing now. Looking at what is happening in a number of Western countries, we are amazed to see the domestic practices — which we, fortunately, have left, I hope — in the distant past. The fight for equality and against discrimination has turned into aggressive dogmatism bordering on absurdity, when the works of the great authors of the past — such as Shakespeare — are no longer taught at schools or universities, because their ideas are believed to be backward. The classics are declared backward and ignorant of the importance of gender or race. In Hollywood, memos are distributed about proper storytelling and how many characters of what color or gender should be in a movie. This is even worse than the agitprop department of the Central Committee of the Communist Party of the Soviet Union.”

This, from the head of the former totalitarian enterprise, against whom we fought a five decades’ long Cold War, risking the entire planet (in a very real manner). This, from the head of a country riven in a literally genocidal manner by ideas that Putin himself attributes to the progressives in the West, to the generally accepting audience of his once-burned (once (!)) twice-shy listeners.

And all of you going along with the DIE activists, whatever your reasons: this is on you. Professors. Cowering cravenly in pretence and silence. Teaching your students to dissimulate and lie. To get along. As the walls crumble. For shame. CEOs: signalling a virtue you don’t possess and shouldn’t want to please a minority who literally live their lives by displeasure. You’re evil capitalists, after all, and should be proud of it. At the moment, I can’t tell if you’re more reprehensibly timid even than the professors. Why the hell don’t you banish the human resource DIE upstarts back to the more-appropriately-named Personnel departments, stop them from interfering with the psyches of you and your employees, and be done with it? Musicians, artists, writers: stop bending your sacred and meritorious art to the demands of the propagandists before you fatally betray the spirit of your own intuition. Stop censoring your thought. Stop saying you will hire for your orchestral and theatrical productions for any reason other than talent and excellence. That’s all you have. That’s all any of us have.

He who sows the wind will reap the whirlwind. And the wind is rising.

On May 7, 2021, during the peak of India's Delta Surge, The World Health Organization reported, "Uttar Pradesh (is) going the last mile to stop COVID-19."

https://www.who.int/india/news/feature-stories/detail/uttar-pradesh-going-the-last-mile-to-stop-covid-19

The WHO noted, "Government teams are moving across 97,941 villages in 75 districts over five days in this activity which began May 5 in India's most populous state with a population of 230 million."

The activity involved an aggressive house-to-house test and treat program with medicine kits.

The WHO explained, "Each monitoring team has two members who visit homes in villages and remote hamlets to test everyone with symptoms of COVID-19 using Rapid Antigen Test kits. Those who test positive are quickly isolated and given a medicine kit with advice on disease management."

The medicines comprising the kit were not identified as part of the Western media blackout at the time. As a result, the contents were as secret as the sauce at McDonald's.

The WHO continued, "On the inaugural day, WHO field officers monitored over 2,000 government teams and visited at least 10,000 households."

This news story was published on the WHO Official Website in India. The website details the WHO’s work against COVID-19 in India, including a discussion about their “Online course for Rapid Response Teams.”

https://www.who.int/india

Such teams are the very government teams discussed above assigned to conduct the house-to-house test and treat program in Uttar Pradesh. In discussing the role of the Rapid Response Team (RRT), the WHO site reports,

“RRTs are a key component of a larger emergency response strategy that is essential for an efficient and effective response…WHO has produced and published this course for RRTs working at the national, sub-national, district, and sub-district levels to strengthen the pandemic response with support from the National Center for Disease Control, Ministry of Health & Family Welfare, Government of India, and the U.S. Centers for Disease Control and Prevention.”

The Rapid Response Teams derive support from the United States CDC under the umbrella of the WHO. This fact further validates the Uttar Pradesh test and treat program and solidifies this as a joint effort by the WHO and CDC.

https://www.who.int/india/news/detail/16-09-2021-online-course-for-rapid-response-teams

Perhaps the most telling portion of the WHO article was the last sentence, “WHO will also support the Uttar Pradesh government on the compilation of the final reports.”

https://www.who.int/india/news/feature-stories/detail/uttar-pradesh-going-the-last-mile-to-stop-covid-19

None have yet been published.

Just five short weeks later, on June 14, 2021, new cases had dropped a staggering 97.1 percent, and the Uttar Pradesh program was hailed as a resounding success. According to ZeeNews of India, "The strategy of trace, test & treat yields results."

"The Yogi-led state has also been registering a steep decline in the number of Active COVID Cases as the figure has dropped from a high of 310,783 in April to 8,986 now, a remarkable reduction by 97.10 percent."

https://zeenews.india.com/uttar-pradesh/cm-yogi-adityanath-s-strategy-of-trace-test-treat-yields-results-contains-second-wave-of-covid-19-2368977.html

By July 2, 2021, three weeks later, cases were down a full 99 percent.

https://www.news18.com/news/india/up-sees-declining-covid-cases-positivity-rate-state-govt-eases-lockdown-curbs-all-you-need-to-know-3918440.html

On August 6, 2021, India’s Ivermectin media blackout ended with MSN reporting. Western media, including MSN, finally acknowledged what was contained in those Uttar Pradesh medicine kits. Among the medicines were Doxycycline and Ivermectin.

https://trialsitenews.com/msn-showcases-the-amazing-uttar-pradesh-turnaround-the-ivermectin-based-home-medicine-kits/

On August 25, 2021, the Indian media noticed the discrepancy between Uttar Pradesh's massive success and other states, like Kerala's, comparative failure. Although Uttar Pradesh was only 5% vaccinated to Kerala's 20%, Uttar Pradesh had (only) 22 new COVID cases, while Kerala was overwhelmed with 31,445 in one day. So it became apparent that whatever was contained in those treatment kits must have been pretty effective.

News18 reported, "Let’s look at the contrasting picture. Kerala, with its 3.5 crore population - or 35 million, on August 25 reported 31,445 new cases, a bulk of the total cases reported in the country. Uttar Pradesh, the biggest state with a population of nearly 24 crore - or 240 million - meanwhile reported just 22 cases in the same period.

Two days ago, just seven fresh positive cases were reported from Uttar Pradesh. Kerala reported 215 deaths on August 25, while Uttar Pradesh only reported two deaths. In fact, no deaths have been reported from Uttar Pradesh in recent days. There are only 345 active cases in Uttar Pradesh now while Kerala’s figure is at 1.7 lakh - or 170,000."

https://www.news18.com/news/india/tale-of-two-states-kerala-uttar-pradesh-paint-a-contrasting-picture-of-covid-19-4127714.html

"Kerala has done a much better job in vaccination coverage with 56% of its population being vaccinated with one dose and 20% of the population being fully vaccinated with a total of 2.66 crore - or 26.6 million - doses being administered.

Uttar Pradesh had given over 6.5 crore - or 65 million - doses, the maximum in the country, but only 25% of people have got their first dose while less than 5% of people are fully vaccinated. Given the present COVID numbers, Uttar Pradesh seems to be trumping Kerala for the tag of the most successful model against COVID."

This author reviewed the reasons behind Kerala’s failed treatment model in two articles, “The Lesson of Kerala” and “Kerala’s Vaccinated Surge.”

https://www.thedesertreview.com/opinion/columnists/indias-ivermectin-blackout---part-iii-the-lesson-of-kerala/article_ccecb97e-044e-11ec-9112-2b31ae87887a.html

https://www.thedesertreview.com/opinion/columnists/indias-ivermectin-blackout---part-iv-keralas-vaccinated-surge/article_8a8c481c-09d3-11ec-a51c-fb063e1a3e3b.html

By September 12, 2021, Livemint reported that 34 districts were declared COVID-free or had no active cases. Only 14 new cases were recorded in the entire state of Uttar Pradesh.

https://www.livemint.com/news/india/uttar-pradesh-34-districts-declared-coronavirus-free-claims-govt-11631413344586.html

On September 22, 2021, YouTube hosted a video by popular science blogger Dr. John Campbell detailing the Uttar Pradesh success story. He gave a breakdown of the ingredients and dosages of the magical medicine home treatment kit responsible for eradicating COVID in Uttar Pradesh. The same kit was also used in the state of Goa.

Dr. John Campbell broke India's Ivermectin Blackout wide open on YouTube by revealing the formula of the secret sauce, much to the dismay of Big Pharma, the WHO, and the CDC. Readers will want to watch this before it is taken down. See mark 2:22.

https://youtu.be/eO9cjy3Rydc

Each home kit contained the following: Paracetamol tablets [tylenol], Vitamin C, Multivitamin, Zinc, Vitamin D3, Ivermectin 12 mg [quantity #10 tablets], Doxycycline 100 mg [quantity #10 tablets]. Other non-medication components included face masks, sanitizer, gloves and alcohol wipes, a digital thermometer, and a pulse oximeter. See mark 2:33.

Campbell reports that the exciting things in the kit that grabbed his attention were: Zinc, Vitamin D3, Ivermectin, and secondary antibiotic treatment. "Interesting, that’s what the government decided to give." See mark 3:40

John Campbell has reviewed repurposed drugs for COVID before. He has interviewed both Dr. Tess Lawrie and Dr. Pierre Kory. Repurposed drugs hold the potential for benefitting many conditions, not the least of which include viruses and cancers.

https://www.amazon.com/Surviving-Cancer-COVID-19-Disease-Repurposed/dp/0998055425

Dr. Campbell noted that there had been no recent cases in 59 Uttar Pradesh districts. In addition, out of 191,446 tests completed in the previous 24 hours, only 33 samples were positive for a test positivity rate of only 0.01%. Dr. Campbell called this low number "staggering." See mark 5:05.

https://youtu.be/eO9cjy3Rydc

By September, cases had fallen dramatically. Out of the entire state of 200 million plus inhabitants, only 187 active cases were left compared to the peak in April of 310,783 cases. See mark 5:41.

Dr. Campbell attributes their success to many factors, including early detection and early treatment with kits costing a mere $ 2.65 per person. See mark 6:20.

Notice that Dr. Campbell does not mention a single person who had any toxicity from those ten 12 mg pills of Ivermectin - in the entire state of over 200 million. Not one poisoning was reported. No Indian poison control articles or telephone calls were reported. Out of millions of distributed medicine kits, each containing 120 mg of Ivermectin, not one person in Uttar Pradesh was reported to have had a problem with the drug.

Notice that Dr. Campbell at no time criticizes the medicine kit as "fringe" or ineffective. After all, it would be improper to accuse a WHO-sponsored program such as the Uttar Pradesh test and treat – coordinated by WHO – of being “fringe.”

https://www.who.int/india/news/feature-stories/detail/uttar-pradesh-going-the-last-mile-to-stop-covid-19

Contrary to what little we receive - at great expense - from the government in the United States, these kits are efficient and contain gloves, a thermometer, and an oximeter. The last time I purchased an oximeter some ten years ago, it cost some $200.00. This entire kit – including the oximeter – costs only $2.65.

And notice that a government can purchase over one thousand home treatment Ivermectin containing kits for the price of one course of Remdesivir. Remdesivir runs $3,100, and it is an impractical drug as it must be given late in the disease during hospitalization. Moreover, it is a drug that does not save lives.

https://www.nejm.org/doi/full/10.1056/nejmoa2007764

https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html

On the other hand, the Ivermectin kits are highly correlated with eliminating COVID-19 in Uttar Pradesh. Indeed with less than 11% of their population fully vaccinated, the Uttar Pradesh model of test and treat is superior not only to Kerala, with a much higher percent vaccinated. Uttar Pradesh beats the UK, the US, and nearly everywhere else in the world in terms of the lowest active COVID cases.

https://timesofindia.indiatimes.com/city/lucknow/1-1-of-up-is-now-fully-vaccinated/articleshow/86354448.cms

https://www.thedesertreview.com/opinion/columnists/indias-ivermectin-blackout---part-iv-keralas-vaccinated-surge/article_8a8c481c-09d3-11ec-a51c-fb063e1a3e3b.html

Rather than turning a blind eye to Uttar Pradesh, perhaps it is time to analyze its success. It is time for all to realize that far from being dangerous, Ivermectin is safer than hand sanitizer or plain Tylenol, judging from the number of United States poison control calls.

https://www.thedesertreview.com/the-ivermectin-deworming-hoax---part-iii-poison-control-exposed/article_a553b7f2-1a31-11ec-881a-a7df53e98d65.html

Now is precisely the moment to point out that Dr. George Fareed, Dr. Peter McCullough, and Dr. Harvey Risch were correct in their U.S. Senate Testimony on November 19, 2020. They advised that early outpatient treatment was essential and would save hundreds of thousands of American lives if adopted. It wasn’t.

https://www.thedesertreview.com/opinion/letters_to_editor/letter-to-the-editor-in-support-of-early-outpatient-treatment-of-covid-19/article_b342aea6-38b2-11eb-bdf7-8bcbd1e8ade4.html

Now is the right moment to notice the onslaught of United States poison control articles attempting to smear Ivermectin, a drug proven safe and effective in the Uttar Pradesh test-and-treat program administered under the auspices of both the WHO and CDC.

It is appropriate to remind the reader that the WHO and CDC possess direct and recent knowledge of Ivermectin use for COVID-19 in India. Moreover, they know better than anyone the colossal effectiveness and overwhelming safety of Ivermectin used in those millions of Uttar Pradesh test and treat kits.

Perhaps it is also time to ask why exactly Dr. Tess Lawrie’s peer-reviewed meta-analysis was given an Altimetric score of 26,697, making it number eight out of some 18 million publications.

https://hopepressworks.org/f/ivermectin-meta-analysis-by-dr-tess-lawrie-nears-most-cited-ever

This rank is far better than the top 1%, which would only need a ranking of 180,000 for it to rank in the top 1%. It would only need 18,000 for it to rank in the top .1%. Ranking in the top .001% would mean #180. Therefore, at number eight, it is 8/180 of the top .001% or roughly the top 4.4% of the top .001%. This article ranks in the top 5% of the top .001%!

In other words, only seven articles in the world out of those 18 million are ranked higher.

This peer-reviewed paper is one of the most cited of medical references of all time – period. That should alert any reader – immediately - to its historical significance. Dr. Tess Lawrie is a 30-year veteran WHO evidence synthesis expert. Her conclusion is every bit as meaningful as the article's rank. Here are those words,

“Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using Ivermectin. Using Ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that Ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.”

https://pubmed.ncbi.nlm.nih.gov/34145166/

Maybe it is time to ask why Dr. Pierre Kory’s peer-reviewed narrative review of Ivermectin ranks #38 out of the same 18 million publications.

He concludes, “Finally, the many examples of Ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality reduction indicate that an oral agent effective in all phases of COVID-19 has been identified.”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/

If Dr. Lawrie’s paper is ranked in the top 5% of the top .001% of all such published medical articles of all time, then Dr. Kory’s is not far behind. His is 38/180 of the top .001% or the top 21% of the top .001%

Thus, both articles would rank in the rarified atmosphere of nearly one in a million.

Therefore, the reader must now ask why two magnificent independent reviews from two different continents, coming to the same conclusion, are both ignored by our world’s medical leaders?

Uttar Pradesh is one such population that experienced a considerable drop in COVID-19 morbidity and mortality months AFTER Dr. Kory’s article was published on April 22, 2021. Therefore, one must ask that if Ivermectin so predictably and safely eradicates COVID-19, then why is it not being systematically deployed over all the world, as Dr. Kory and Dr. Lawrie suggest?

Perhaps every reader needs to ask themselves this question - Why is it that BOTH Dr. Lawrie’s and Dr. Kory’s supremely-rated expert review articles, published in the medical literature on PubMed, the National Library of Medicine, are BANNED from Wikipedia?

https://www.thedesertreview.com/opinion/columnists/wikipedia-and-a-pint-of-gin/article_22ffa0d8-dde9-11eb-be75-d7b0b1f2ff67.html

Although India’s Ivermectin victory over COVID may have been lost on bent-on-vaccinating-everyone Big Pharma and Big Regulators, the message seems to have gotten through to the man on the street. If Google Trends is any indicator, interest in Ivermectin is exploding, and for good reason. We are all being systematically deceived by influential organizations in the name of profits.

https://www.thedesertreview.com/opinion/columnists/gaslighting-ivermectin-vaccines-and-the-pandemic-for-profit/article_19f42a96-05c5-11ec-8172-d776656bad51.html

https://trialsitenews.com/is-the-ivermectin-situation-rigged-in-favor-of-industry-is-the-big-tobacco-analogy-appropriate/

A daily onslaught of media propaganda bombards us with messages attempting to steer us away from the safest and most effective treatments.

https://www.thedesertreview.com/opinion/columnists/the-ivermectin-deworming-hoax---part-ii-eric-clapton-s-human-rights-warning/article_284902bc-14be-11ec-8d43-43e98275cff8.html

Interest in Ivermectin and India is only increasing and has now reached an all-time high. India’s conquest of COVID-19 is concealed no longer. The secret is out. And perhaps, at long last, that much-anticipated WHO Final Report detailing the most successful Pandemic campaign of any place on earth will be published.

I recently spoke at a gathering for medical freedom advocates in a little community center in the Hudson River Valley. I cherish this group of activists: they had steadfastly continued to gather throughout the depths of the “lockdown,” that evil time in history — an evil time not yet behind us — and they kept on gathering in human spaces, undaunted. And by joining their relaxed pot-luck dinners around unidentifiable but delicious salads and chewy homemade breads, I was able to continue to remember what it meant to be part of a sane human community.

Children played — as normal — frolicking around, and speaking and laughing and breathing freely; not suffocating in masks like little zombies, or warned by terrified adults to keep from touching other human children. Dogs were petted. Neighbors spoke to one another at normal ranges, without fear or phobias. Bands played much-loved folk songs or cool little indie rock numbers they had written themselves, and no one, graceful or awkward, feared dancing. People sat on the house’s steps shoulder to shoulder, in human warmth, and chatted over glasses of wine or homemade cider. No one asked anyone personal medical questions.

(While I believe that all decisions about how you live your life vis a vis an infectious disease are intensely personal, and I would never recommend to others to assume any specific level of risk or to pursue any specific strategy of risk reduction; I think it’s worth noting, by the way, that to my knowledge, they had gone through the last two years without having lost a soul to COVID.)

Meanwhile, what had been human community outside of that little group, and outside other isolated normal communities — and outside of a handful of normal states in America — became more and more surreal, terrifying and unrecognizable.

The rest of the world, at least on the progressive side in the United States, became increasingly cult-like and insular in its thinking, since March of 2020. As the months passed, friends and colleagues of mine who were highly educated, and who had been lifelong critical thinkers, journalists, editors, researchers, doctors, philanthropists, teachers, psychologists — all began to repeat only talking points from MSNBC and CNN, and soon overtly refused to look at any sources - even peer-reviewed sources in medical journals — even CDC data — that contradicted those talking points. These people literally said to me, “I don’t want to see that; don’t show it to me.” It became clear soon enough that if they absorbed information contradictory to “the narrative” that was consolidating, they risked losing social status, maybe even jobs; doors would close, opportunities would be lost. One well-educated woman told me she did not want to see any unsanctioned information because she was afraid of being disinvited from her bridge group. Hence the refrain: “I don’t want to see that; don’t show it to me.”

Friends and colleagues of mine who had been skeptical their whole adult lives of Big Agriculture — who only shopped at Whole Foods, who would never let their kids eat sugar or processed meat, or ingest a hint of Red Dye No 2 in candy, or eat candy itself for that matter in some cases — these same people lined up to inject into their bodies, and then offered up the bodies of their dependent minor children for the same purpose, an MRNA gene-therapy injection whose trials would not end for two more years. These parents announced on social media proudly that they had done this with their children. When I pointed out gently that the trials would not end til 2023, they yelled at me.

The progressive, right-on part of the ideological world — my people, my tribe, my whole life — became more and more uncritical, less and less able to reason. Friends and colleagues who were wellness-oriented, and who their whole adult lives had known the dangers of Big Pharma — and who would only use Burt’s Bees on their babies’ bottoms and sunscreen with no PABAs on themselves— lined up to take an experimental gene therapy; why not? And worse, it seemed, they crowded around, like the stone throwers in Shirley Jackson’s short story “The Lottery,” to lash out at and to shun anyone who raised the most basic questions about Big Pharma and its highly compensated spokesmodels. Their critical thinking, but worse, their entire knowledge base about that industry, seemed to have evaporated magically into the ether.

Whole belief systems were abandoned painlessly and overnight as if it these communities were in the grip of a collective hallucination, like the witch craze of the 15th to 17th centuries in Northern Europe. Intelligent, informed people suddenly saw things that were not there and were unable to see things that were incontrovertibly before their faces.

Feminist health activists, who surely knew perfectly well the histories of how the pharmaceutical and medical industries had experimented ad nauseam on the bodies of women with disastrous results, lined up to take an injection that by March of 2021 women were reporting was wreaking painful havoc on their menstrual cycles. These same feminist health activists had spoken out earlier, as they should have, about Big Pharma’s and Big Medicine’s colonization of women’s reproductive health processes, and had spoken out about issues ranging from women’s access to safe contraception to abortion rights, to the rights of mothers to a midwifery delivery or to a birthing room, or to the right to labour or the right to store milk at work or the right to breastfeed in public.

But these formerly reliable custodians of well-informed medical skepticism and of women’s health rights, were silent, silent, as such voices as former HHS official Dr Paul Alexander warned that spike protein from MRNA vaccines may accumulate in the ovaries (and testes), https://www.clarkcountytoday.com/news/pfizer-covid-19-vaccine-delivers-less-long-term-protection-from-hospitalization-after-four-months/, and as vaccinated women reported hemorrhagic menses — double digit percentages in a Norwegian study reported heavier bleeding (https://www.fhi.no/en/news/2021/menstrual-changes-following-covid-19-vaccination/). Many women also reported blood clotting, and women even reported post-menopausal bleeding — and mothers reported their vaccinated twelve year olds suddenly getting their periods; but it was two periods a month some girls endured.

Almost no one out of the luminaries of feminist health activism who had spent decades speaking out on behalf of women’s health and women’s bodies, raised a peep above the parapet. Those two or three of us who did were very visibly smeared, in some cases threatened, and in many ways silenced.

When I broke this story of menstrual dysregulation post-vaccination on Twitter in Spring of 2021, I was suspended. Matt Gertz works at CNN and Media Matters. The former is a channel on which I had appeared for decades; the latter, a group whose leadership members I’ve known for years, and in one instance, with whom I’ve worked.

In spite of both of his employers having sought out professional association with me, Matt Gertz publicly and repeatedly called me a “pandemic conspiracy theorist” upon my first having reported on menstrual dysregulation, and elsewhere accused me of “crack-pottery” https://www.mediamatters.org/fox-news/fox-keeps-hosting-pandemic-conspiracy-theorist-naomi-wolf.

Shame on me for doing journalism. I broke the post-vaccination menstrual dysregulation story by doing what I always do: by using the same methodology that I used in writing The Beauty Myth (about eating disorders) and Misconceptions (about obstetrics), and Vagina (about female sexual health): I listened to women, that radical act.

The New York Times just re-broke my story of menstrual dysregulation, ten months later, January 2022, in a different year, https://www.nytimes.com/2022/01/06/health/covid-vaccine-menstrual-cycles.html, after perhaps millions of women readers may have been physically harmed by their lack of decent reporting and their uncritical acceptance of soundbites from captured regulatory authorities. There has been no retraction or apology from Mr Gertz, from The New York Times, or from other news outlets such as DailyMail.co.uk, who all then called me crazy but are now reporting my story as if it is their own — now that it’s clear that, once again, sadly, I was right.

Feminist health advocates who know about routine hysterectomies at menopause, about vaginal mesh that has to be removed, about silicone breasts implants that leaked or burst and had to be recalled or replaced, about Mirena that had to be removed, about Thalidomide that deformed babies’ limbs in utero, about birth control pills at hormonal doses that heightened heart attack risks and stroke risks and that lowered the female libido; about routine c-sections to speed up turnover at hospitals, about the sterilization of low income women and girls and women and girls of color without informed consent — were silent about the unproven nature of MRNA vaccines, and about coercive policies that violated the Nuremberg code and other laws, as a whole generation of young women who have not yet had their babies, was forced to take an MRNA vaccine (and sometimes second vaccine, and booster) with unproven effects on reproductive health, in order simply to return to campus or to get or to keep a job. The Our Bodies Ourselves collective? Nothing on vaccine risks and women’s health as a subject category: https://www.ourbodiesourselves.org/book-excerpts/. NARAL? Where were they? Crickets. Where were all the responsible feminist health activists, in the face of this global, unconsenting, uninforming, illegal experimentation on women’s bodies, and now on children, and soon, on babies?

People who had been up in arms for decades about eating disorders or about the coercive social standards that led to — horrors — leg shaving, were silent about an untested injection that was minting billions for Big Pharma; an injection that entered, according to Moderna’s own press material, every cell in the body, which would thus include involving uterus, ovaries, endometrium.

The sudden amnesia extended to feminist legal theory. Feminist jurists such as Justice Sotomayor and Justice Kagan debated President Biden’s vaccine mandates on January 7 — as if they had never heard of the legal claims for Roe v Wade: privacy law. As Politico reported of Justice Kagan, “The Supreme Court’s ruling on privacy rights served as a basis for its later decision, Roe v Wade” and as former Sen. Barbara Boxer had stated, “I have no reason to think anything else except that [Kagan] would be a very strong supporter of privacy rights because everyone she worked for held that view.” https://www.politico.com/story/2010/06/kagan-must-explain-abortion-stance-039096.

Except…now they seemingly don’t, and now Justice Kagan magically doesn’t. With medical mandates, there are no privacy rights for anyone ever.

But Justice Kagan seemed suddenly, after decades of this view, not to see a contradiction. Her career-long philosophical foundation that resulted in a consistent view, when it came to abortion rights, that citizens had a right to physical privacy in medical decision-making — “My body, my choice” — “It is between a woman and her doctor” — vanished, along with her expensive education and all of her knowledge of the Constitution.

Justice Sotomayor, for her part, said, in an article reported on Dec 10 2021, that it was “madness” that the state of Texas wanted to “substantially suspend[ed] a constitutional guarantee: a pregnant woman’s right to control her own body.” Her tone was, rightly, one of high dudgeon at the thought that anyone might override this right. But when it came to Justice Sotomayor’s discussion on Jan 7 2022, less than four weeks later, of President Biden’s vaccine mandates, that clear Constitutional right was now nowhere to be seen; it too had vanished into the ether. A part of Justice Sotomayor’s brain seems to have simply shut down at the word “vaccines” — though it was the same woman in the same Court, with the same Constitution before her, the Justice could no longer manage the Kantian imperative of consistent reasoning. https://www.theguardian.com/us-news/2021/dec/10/supreme-court-abortion-ruling-texas-ban

Lifelong activists for justice and inclusion, for the Constitution and human rights and the rule of law — friends and colleagues of mine who are LGBTQ rights activists; the ACLU itself; activists for racial inclusion and equality; Constitutional lawyers who teach at all the major universities and run the law reviews; activists who argue against excluding anyone from any profession or access based on gender; almost all of them, at least on the progressive side of the spectrum (almost all: hello, Glenn Greenwald) — were silent; as a comprehensive, systematic, cruel, Titanic discrimination society was erected in a matter of months in such cities as New York City, formerly the great melting pot, the great equalizer; and as whole states such as California adopted a system pretty much like the apartheid systems based on other physical characteristics, in regimes that these same proud advocates for equality and inclusion had boycotted in college.

And yet now these former heroes for human rights and for equal justice under law, stood by calmly or even enthusiastically as the massive edifice of discrimination was constructed. And then they colluded. Without even a fight or a murmur.

And they had their “vaccinated-only” parties, and their segregated fashion galas, and their nonprofit-hosted discussions in nice medically-segregated New York City midtown hotels over expensive lunches served by staffers in masks — lunches celebrating luminaries of the civil rights movement or of the LGBTQ rights movement or the immigrants’ rights movement, or the movement to help girls in Afghanistan get access to schools which they had been prevented from attending— invitations which I received, but of which I could not make use, because — because I was prevented from attending.

And these elite justice advocates enjoyed the celebrations of their virtues and of their values, and did not seem to notice that they had become — in less than a year — exactly what they had spent their adult lives professing most to hate.

I could go on and on.

The bottom line, though, is that this infection of the soul, this abandonment of classical Liberalism’s — really, it’s not even partisan; modern civilization’s — most cherished postwar ideals, this sudden dropping of post-Enlightenment norms of critical thinking, this dilution even of parents’ sense of protectiveness over the bodies and futures of their helpless minor children, this acceptance of a world in which people can’t gather to worship, these suddenly-manifested structures themselves that erected this demonic world in less than two years and imposed it on everyone else, these heads of state and heads of the AMA and heads of school boards and these teachers; these heads of unions and these national leaders and the state level leaders and the town hall level functionaries all the way down to the men or woman who disinvite a relative from Thanksgiving due to social pressure, because of a medical status which is no one’s business and which affects no one — this edifice of evil is too massive, too quickly erected, too complex and really, too elegant, to assign to just human awfulness and human inventiveness.

Months before, I had asked a renowned medical freedom activist how he stayed strong in his mission as his name was besmirched and he faced career attacks and social ostracism. He replied with Ephesians 6:12: “For we wrestle not against flesh and blood, but against principalities, against powers, against the rulers of the darkness of this world, against spiritual wickedness in high places.” https://www.biblegateway.com/passage/?search=Ephesians%206%3A12&version=KJV

I had thought of that a lot in the intervening time. It made more and more sense to me as the days passed.

I confessed at that gathering in the woods with the health freedom community, that I had started to pray again. This was after many years of thinking that my spiritual life was not that important, and certainly very personal, almost embarrassingly so, and thus it was not something I should mention in public.

I told the group that I was now willing to speak about God publicly, because I had looked at what had descended on us from every angle, using my normal critical training and faculties; and that it was so elaborate in its construction, so comprehensive, and so cruel, with an almost superhuman, flamboyant, baroque imagination made out of the essence of cruelty itself — that I could not see that it had been accomplished by mere humans working on the bumbling human level in the dumb political space.

I felt around us, in the majestic nature of the awfulness of the evil around us, the presence of “principalities and powers” — almost awe-inspiring levels of darkness and of inhuman, anti-human forces. In the policies unfolding around us I saw again and again anti-human outcomes being generated: policies aimed at killing children’s joy; at literally suffocating children, restricting their breath, speech and laughter; at killing school; at killing ties between families and extended families; at killing churches and synagogues and mosques; and, from the highest levels, from the President’s own bully pulpit, demands for people to collude in excluding, rejecting, dismissing, shunning, hating their neighbors and loved ones and friends.

I have seen bad politics all of my life and this drama unfolding around us goes beyond bad politics, which is silly and manageable and not that scary. This — this is scary, metaphysically scary. In contrast to hapless human mismanagement, this darkness has the tinge of the pure, elemental evil that underlay and gave such hideous beauty to the theatrics of Nazism; it is the same nasty glamour that surrounds Leni Riefenstahl films.

In short, I don’t think humans are smart or powerful enough to have come up with this horror all alone.

So I told the group in the woods, that the very impressiveness of evil all around us in all of its new majesty, was leading me to believe in a newly literal and immediate way in the presence, the possibility, the necessity of a countervailing force — that of a God. It was almost a negative proof: an evil this large must mean that there is a God at which it is aiming its malevolence.

And that is a huge leap for me to take, as a classical Liberal writer in a postwar world, — to say these things out loud.

Grounded postmodern intellectuals are not supposed to talk about or believe in spiritual matters — at least not in public. We are supposed to be shy about referencing God Himself, and are certainly are not supposed to talk about evil or the forces of darkness.

As a Jew I come from a tradition in which Hell (or “Gehenom”) is not the Miltonic Hell of the later Western imagination, but rather a quieter interim spiritual place (https://jel.jewish-languages.org/words/183). “The Satan” exists in our literature (in Job for example) but neither is this the Miltonic Satan, that rock star, but a figure more modestly known as “the accuser.”

We who are Jews, though, do have a history and literature that lets us talk about spiritual battle between the forces of God and negative forces that debase, that profane, that seek to ensnare our souls. We have seen this drama before, and not that long ago; about eighty years ago.

Other faith traditions of course also have ways to discuss and understand spiritual battle taking place through humans, and through human leaders, and here on earth.

It was not always the case that Western intellectuals were supposed to keep quiet in public about spiritual wrestling, fears and questions. Indeed in the West, poets and musicians, dramatists and essayists and philosophers, talked about God, and even about evil, for millennia, as being at the core of their understanding of the world and as forming the basis of their art forms and of their intellectual missions. This was the case right through the nineteenth century and into the first quarter of the 20th, a period when some of our greatest intellectuals — from Darwin to Freud to Jung — wrestled often and in public with questions of how the Divine, or its counterpart, manifested in the subjects they examined.

It was not until after World War Two and then the rise of Existentialism — the glorification of a world view in which the true intellectual showed his or her mettle by facing the absence of God and our essential aloneness — that smart people were expected to shut up in public about God.

So - it’s not wacky or eccentric, if you know intellectual history, for intellectuals to talk in public about God, and even about God’s adversary, and to worry about the fate of human souls. Mind and soul are not in fact at odds; and the body is not in fact at odds with either of these. And this acceptance of our three-part, integrated nature is part of our Western heritage. This is a truth only recently obscured or forgotten; a memory of our integrity as human beings that had been, only for the last seventy years or so, under attack.

So — I am going to start talking about God, when I need to do so, and about my spiritual questions in this dark time, along with continuing all of the other reporting and nonfiction analysis I always do. Because I have always told my readers the truth of what I felt and saw. This may be why they have come with me on a journey now of almost forty-three years, and why they keep seeking me out — though I have in the last couple of years — after I wrote a book that described how 19th century pandemics were exploited by the British State to take away everyone’s liberty, hm — been pulped, deplatformed, cancelled, re-cancelled, deplatformed again, and called insane by dozens of the same news outlets that had commissioned me religiously for decades.

It is time to start talking about spiritual combat again, I personally believe. Because I think that that is what we are in, and the forces of darkness are so big that we need help. Our goal? Perhaps just to keep the light somehow alive - a light of true classical humane values, of reason, of democracy, inclusion, kindness - in this dark time.

What is the object of this spiritual battle?

It seems to be for nothing short of the human soul.

One side seems to be wrestling for the human soul by targeting the human body that houses it; a body made in God’s likeness, so they say; the temple of God.

I am not confident. I don’t have enough faith. Truth is, I am scared to death. I just don’t think just humans alone can solve this one, or can win this one on their own.

I do think we need to call, as Milton did, as Shakespeare did, as Emily Dickinson did, on help from elsewhere; on what could be called angels and archangels, if you will; on higher powers, whatever they may be; on better principalities, on whatever intercessors may hear us, on Divine Providence — whatever you want to call whomever it is you can hope for and imagine. As I often say, I’ll take any faith tradition. I’ll talk to God in any language — I don’t think forms really matter. I think intention is everything.

I can’t say for sure that God and God’s helpers exist; I can’t. Who can?

But I do think we are at an unheard-of moment in human history — globally — in which I personally believe we have no other choice but to ask for assistance from beings — or a Being — better armed to fight true darkness, than ourselves alone. We’ll find out if they exist, if He or She exists, perhaps, if we ask for God’s help.

At least that’s my hope.

Which I guess is a kind of a prayer.

_ [This was an answer to the 2013 edge.org question, What should we be worried about? That link is the official page. And this is an archive.org capture of that page, What should be worried about?

Scroll down about a third, and right between Naughton and Scheiner, the archive has answer by mathematician Steven Strogatz, which is missing from the newest version, even though the count at the top still says there are 155 responses. This is the missing response in full.] _

In every realm where we exist as a collective -- in society, in the global economy, on the Internet -- we are blithely increasing the coupling between us, with no idea what that might entail.

"Coupling" refers to the ability of one part of a complex system to influence another. If I put a hundred metronomes on the floor and set them ticking, they'll each do their own thing, swinging at their own rhythm. In this condition, they're not yet coupled. Because the floor is rigid, the metronomes can't feel each other's vibrations, at least not enough to make a difference. But now place them all on a movable platform like the seat of a child's swing. The metronomes will start to feel each other's jiggling. The swing will start to sway, imperceptibly at first, but enough to disturb each metronome and alter its rhythm. Eventually the whole system will synchronize, with all the metronomes ticking in unison. By allowing the metronomes to impose themselves on each other through the vibrations they impart to the movable platform, we have coupled the system and changed its dynamics radically.

In all sorts of complex systems, this is the general trend: increasing the coupling between the parts seems harmless enough at first. But then, abruptly, when the coupling crosses a critical value, everything changes. The exact nature of the altered state isn't easy to foretell. It depends on the system's details. But it's always something qualitatively different from what came before. Sometimes desirable, sometimes deadly.

I worry that we're playing the coupling game with ourselves, collectively. With our cell phones and GPS trackers and social media, with globalization, with the coming Internet of things, we're becoming more tightly connected than ever. Of course, maybe that's good. Greater coupling means faster and easier communication and sharing. We can often do more together than apart.

But the math suggests that increasing coupling is a siren's song. Too much makes a complex system brittle. In economics and business, the wisdom of the crowd works only if the individuals within it are independent, or nearly so. Loosely coupled crowds are the only wise ones.

The human brain is the most exquisitely coupled system we know of, but the coupling between different brain areas has been honed by evolution to allow for the subtleties of attention, memory, perception, and consciousness. Too much coupling produces pathological synchrony: the rhythmic convulsions and loss of consciousness associated with epileptic seizures.

Propagating malware, worldwide pandemics, flash crashes -- all symptoms of too much coupling. Unfortunately it's hard to predict how much coupling is too much. We only know that we want more, and that more is better... until it isn't.